Mast Cell Function: A New Vision of an Old Cell

Elaine Zayas Marcelino da Silva, Maria Célia Jamur, and Constance Oliver
Department of Cell and Molecular Biology and Pathogenic Bioagents, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil (EZMDS, MCJ, CO)

Summary
Since first described by Paul Ehrlich in 1878, mast cells have been mostly viewed as effectors of allergy. It has been only in the past two decades that mast cells have gained recognition for their involvement in other physiological and pathological processes. Mast cells have a widespread distribution and are found predominantly at the interface between the host and the external environment. Mast cell maturation, phenotype and function are a direct consequence of the local microenvironment and have a marked influence on their ability to specifically recognize and respond to various stimuli through the release of an array of biologically active mediators. These features enable mast cells to act as both first responders in harmful situations as well as to respond to changes in their environment by communicating with a variety of other cells implicated in physiological and immunological responses. Therefore, the critical role of mast cells in both innate and adaptive immunity, including immune tolerance, has gained increased prominence. Conversely, mast cell dysfunction has pointed to these cells as the main offenders in several chronic allergic/ inflammatory disorders, cancer and autoimmune diseases. This review summarizes the current knowledge of mast cell function in both normal and pathological conditions with regards to their regulation, phenotype and role. (J Histochem Cytochem 62:698–738, 2014)

Keywords
Mast cells, origin, function, mediators, activation, immunity

Introduction
First described by Paul Ehrlich in 1878 (Ehrlich 1878), mast cells have been viewed, for the most part, as effectors of allergy, particularly in the early and acute phases of allergic reactions. Early research on these cells relied on morphological features (Fig. 1) to identify their distribution in physiological and pathological states. The functional implications of Ehrlich’s initial view of mast cells, as metachromatic, granulated cells implicated in the nutrition of the surrounding tissue evolved gradually. In 1937, Holmgren and Willander (1937) first observed that tissues that displayed a great number of “Ehrlichschen Mastzellen” (mast cells) were enriched in heparin. The following 15 years witnessed the establishment of a relationship between mast cells, histamine, and anaphylaxis, which was supported by the discovery that histamine was present in mast cells (Riley and West 1952) and released, along with heparin, during anaphylactic shock (Rocha e Silva 1947). Prausnitz and Kustner (1921) demonstrated years earlier that the immediate hypersensitivity skin reaction could be transferred from a responsive person to a nonresponsive one, indicating that allergic reactions were due to the presence of a “reaginic” substance in the blood. It was not until 1967 that Ishizaka and Ishizaka identified the “reaginic” antibody as being γE antibodies, subsequently recognized as IgE. Later, it was observed that IgE was capable of mediating the release of histamine and another “slow reacting substance” from sensitized tissue mast cells (Ishizaka et al. 1970). These discoveries paved the way for mast cells to become famous for their role in Type I hypersensitivity.

Received for publication March 18, 2014; accepted July 7, 2014.

Corresponding Author:
Constance Oliver, PhD, Department of Cell and Molecular Biology and Pathogenic Bioagents, Ribeirão Preto Medical School, University of São Paulo, Avenida Bandeirantes, 3900, Ribeirão Preto 14049-900, SP, Brazil. E-mail: coliver@fmrp.usp.br
reactions. These reactions, best known as IgE-mediated allergic reactions, are induced when multivalent antigens crosslink antigen-specific IgE bound to high-affinity IgE receptors (FcεRI) on the mast cell surface, thereby aggregating FcεRI and promoting the immediate release of mast cell mediators and the successive adverse events most commonly associated with allergy; i.e., increased vascular permeability, smooth muscle contraction, and mucus secretion (Metzger 1992; Kinet 1999; Siraganian 2003).

Advances in understanding the process of mast cell activation and the effects their mediators have on the immune system revealed the complexity and multiphasic nature of allergic reactions. In addition to the acute immediate events, the allergic process includes later phases marked by leukocyte infiltration and the initiation of an acquired immune response, followed by a chronic phase that includes persistent inflammation, tissue remodeling, and fibrosis (Rao and Brown, 2008). A role for mast cells in these various phases thus gained increased importance (Grimbaldeston et al. 2006; Brown et al. 2008).

The unraveling of mast cell functions, in addition to their established and extensively studied role in IgE-mediated reactions, has been the focus of mast cell research in the past decades. Nevertheless, the identification of mast cell functions has progressed slowly due to difficulties in accessing these cells in vivo and the obstacles encountered when obtaining them both by enzymatic dispersion of tissues or by culture of mast cell progenitors isolated from the bone marrow, peripheral or umbilical cord blood. The culture of mast cell progenitors yields a small number of mast cells and is often expensive and time consuming, and results in variable phenotypes as a consequence of culture conditions (Moon et al. 2010).

The use of mast cell lines has greatly facilitated the characterization of various aspects of mast cell function. However, as transformed cells, they present limitations and the results obtained through their use must be interpreted cautiously when extrapolating to mast cell functions in vivo. Mouse strains that are deficient in mast cells due to mutations in the Kit or Stem Cell Factor (SCF) gene (Kit<sup>W/W-v</sup>, Kit<sup>W-sh</sup>, and Sl/Sld) have served as valuable tools for defining and inferring mast cell functions in vivo (Kitamura et al. 1978; Russell 1979; Grimbaldeston et al. 2005). However, these mice bear several other abnormalities resulting from Kit’s role in other cells, which include erythrocytes, neutrophils and melanocytes, as well as other cell lineages. The engraftment of bone marrow or bone marrow-derived mast cells (BMMCs) in these deficient strains has helped to shed light on mast cell origin and to reliably establish connections between mast cell functions in vivo and their involvement in several diseases (Kitamura et al. 1977; Kitamura et al. 1978; Grimbaldeston et al. 2005; Galli and Tsai 2008; Jamur and Oliver 2011).

The generation of alternative mast cell-deficient mouse strains that were not dependent on Kit mutations was recently reported (Dudeck et al. 2011; Feyerabend et al. 2011; Lilla et al. 2011; Otsuka et al. 2011). One is the result of the targeted insertion of Cre-recombinase into the mast cell carboxipeptidase A3 locus. This resulted in a complete absence of mast cells without any effects on other immune cells except a small reduction in basophil numbers (Feyerabend et al. 2011). The other three mouse models for
mast cell deficiency were concurrently reported: Dudeck et al. reported the development of Mcpt5-Cre mouse models with an inducible or constitutive deficiency in connective tissue type mast cells, also without any effect on other immune cells (Dudeck et al. 2011); Otsuka et al. generated the Mas-TRECK transgenic mice in which both mast cells and basophils are conditionally depleted by diphtheria toxin treatment (Otsuka et al. 2011); and Lilla et al. reported the generation of C57BL/6-Cpa3-Cre;Mcl-1^{fl/fl} mice, which are severely deficient in mast cells and basophils (Lilla et al. 2011). These new mouse models for mast cell deficiency will certainly contribute to and expand upon the current knowledge of mast cell function both in physiological and pathological conditions.

Today, mast cells are considered to be multifunctional immune cells implicated in several health and disease states. It is increasingly evident that mast cell maturation, phenotype, and function are a direct consequence of the local microenvironment and have a marked influence on their ability to specifically recognize and respond to various stimuli through the release of an array of biologically active mediators (Galli et al. 2011). The extensive tissue distribution and versatility of mast cells endow them with the potential to not only act as first responders in harmful situations but also to react to environmental changes by communicating with a variety of other cells implicated in physiological and immunological responses. In addition to their involvement in physiological processes such as tissue repair, wound healing, and angiogenesis, mast cells are increasingly becoming accepted as having a crucial role in innate and adaptive immunity, including immune tolerance.

The capacity of mast cells to promptly interact with the microenvironment and respond through the release of an array of biologically active mediators is a delicate balance where the inadequate regulation of mast cell functions can result in devastating effects to the organism. Hence, mast cells have been implicated in the pathogenesis of several chronic allergic/inflammatory disorders, autoimmune diseases, and cancers (Rao and Brown 2008). The contributions of mast cells in these disease states are the object of continuous assessment. This review focuses on these and other newly acknowledged functional aspects of this ancient cell. Phenotypic plasticity, regulation, and functional outcome in both normal and pathological conditions will be discussed.

Origin

Phylogenetic studies point to the appearance of a possible primitive counterpart of vertebrate mast cells in Ciona intestinalis, a 550-million-year-old urochordate regarded as ancestor of both cephalochordates and vertebrates. This primitive mast cell-like cell contains metachromatic, electron-dense granules and resembles connective tissue mast cells, and is also able to release histamine and prostaglandins upon activation. Accordingly, mast cells could have evolved long before the development of an adaptive immune response (Stevens and Adachi 2007).

Although mammalian mast cells were first described more than a century ago, their origin remained controversial for several decades. Due to their association with connective tissue, it was initially assumed that mast cells were derived from undifferentiated mesenchymal cells (Combs 1966). Lymphocytes, multipotent progenitors, and myeloid cells have also been suggested as mast cell precursors (Yong 1997; Chen et al. 2005; Arinobu et al. 2009; Franco et al. 2010). Owing to morphological and physiological similarities, basophils were also pointed to being mast cell precursors, and a bi-potent, committed progenitor for both cells was identified in the mouse spleen (Zucker-Franklin 1980; Arinobu et al. 2005).

The hematopoietic origin of adult mast cells was established by the pioneering work of Kitamura et al. in 1977. When the bone marrow from beige mice (C57Bl Bg’/Bg”) was transplanted into irradiated wild type C57Bl mice, tissue mast cells with large abnormal granules from the beige mouse bone marrow appeared in the tissue of the recipient mice. This finding, which suggested that mast cells derived from bone marrow precursor cells, was reinforced when the mast cell population in deficient mice (W/W^v) could be reconstituted by bone marrow from wild type mice (Kitamura et al. 1978). The hematopoietic origin of human mast cells was also confirmed after allogeneic bone marrow transplantation in a leukemic patient, where 198 days after the transplant, mast cells isolated from the recipients’ bone marrow displayed the donor’s genotype (Födinger et al. 1994).

The existence of a mast cell committed precursor (MCcp) has been described in mouse bone marrow. Using sequential immunomagnetic isolation with two cell-specific antibodies (mAb AA4 and mAb BGD6), Jamur and colleagues (Jamur et al. 2005) isolated and characterized a MCcp from the bone marrow of adult Balb/c mice (Fig. 2). This precursor cell was CD34^+CD13^-c-Kit^-FceRI^-, and contained mRNA for the α and β subunits of FceRI as well as for the mast cell-specific proteases mMCP-5, mMCP-7, and mouse carboxypeptidase A (CPA). Moreover, the MCcp gave rise only to mast cells in vitro and were able to reconstitute mast cells in lethally irradiated mice. Chen et al. (2005) also identified a putative MCcp in the bone marrow of C57BL/6 mice, which was Lin^−, Sea-1^−, c-Kit^−, Ly6c^−, FceRIα^−, CD27^−, β7^−, and T1/ST2^−, and gave rise only to mast cells in culture. These cells were able to reconstitute mast cells in Kit^W-sh/Kit^W-sh mice. The authors also proposed the existence of a common precursor for mast cells and other myeloid cells within the multipotent progenitor population in the bone marrow (Chen et al. 2005).
The embryonic origin of mast cells has also been a matter of great debate. Earlier, indirect studies indicated the liver and yolk sac as sites of embryonic mast cell origin but the lack of specific markers made it difficult to distinguish between mast cell precursors and pluripotent stem cells (Kitamura et al. 1979; Sonoda et al. 1983; Palis et al. 1999; Medvinsky et al. 2011). Using previously characterized, direct immunological methods, Guiraldelli et al. have recently described, for the first time, the aorta-gonad-mesonephros (AGM) region as the site of origin of rat embryonic mast cells (Jamur et al. 2005; Guiraldelli et al. 2013). The AGM is a region of embryonic mesoderm that develops from the para-aortic splanchnopleura mesoderm in chick, mouse and human embryos. During mouse development, the AGM is the site where definitive hematopoiesis initiates between E10.5 and E12 (Müller et al. 1994; Medvinsky and Dzierzak 1996; de Bruijn et al. 2000; Cumano et al. 2001; Dzierzak and Speck 2008). Therefore, the MCcps found in the AGM at E11.5 appeared concurrently with the initiation of definitive hematopoiesis in mouse embryos (Guiraldelli et al. 2013). These embryonic MCcps were very similar to the adult MCcps previously described and gave rise only to mast cells in vitro (Jamur et al. 2005; Guiraldelli et al. 2013).

**Distribution**

Mast cells have a widespread tissue distribution and are found predominantly at the interface between the host and the external environment (Fig. 1a) at places of potential entry of pathogens or contact with harmful substances, such as skin, respiratory mucosa, and gastrointestinal tract (Ehrlich, 1878; Metcalfe et al. 1997; Galli et al. 2005b; Jamur, 2005; Metcalfe and Boyce, 2006). Mast cells populate connective tissue, particularly in sub-epithelial regions and in the connective tissue surrounding blood vessels, nerves, smooth muscle cells, mucus glands, and hair follicles (Galli et al. 2005a). The far-reaching distribution of the mast cell population relies on mechanisms of constitutive homing, enhanced recruitment, survival, and local maturation of mast cell progenitors. Unlike other cells of hematopoetic origin, which differentiate and mature in the bone marrow before being released to the blood stream, mast cells migrate as immature progenitor cells through the blood stream to peripheral tissues where they complete their maturation (Kitamura et al. 1985; Kitamura et al. 1993; Huff et al. 1995; Hallgren and Gurish 2007). Studies using peripheral resident progenitor cells from the thymus and lymph nodes of rodents and the connective tissue sheath of mouse fibrisa hair follicles showed that progenitor mast cells are present in peripheral tissues and are able to differentiate and mature in vitro (Ginsburg 1963; Ginsburg and Sachs 1963; Ginsburg and Lagunoff 1967; Ishizaka et al. 1976; Ishizaka et al. 1977; Ito et al. 2010). Limiting dilution and colony-forming assays provided evidence that colony-forming mast cells reside in the bone marrow, spleen, peripheral blood, mesenteric lymph nodes, and in the gastrointestinal mucosa (Crapper and Schrader 1983; Guy-Grand et al. 1984; Kasugai et al. 1995). Resident mast cells are long-lived cells that can survive for up to 12 weeks in the skin of Wistar rats (Kiernan 1979). Under specific conditions, mature mast cells are able to proliferate after appropriate stimuli (Kitamura 1989; Galli et al. 2005b; Ryan et al. 2007). In rodents, the recruitment of mast cell progenitors from the bone marrow as well as the proliferation of recently recruited progenitors are responsible for repopulation of the peritoneal cavity after mast cell depletion by distilled water injection (Kanakura et al. 1988a; Jamur et al. 2010). Nakano et al. (1985) observed that reconstitution of the mast cell-deficient WBB6F1-W/W' mice with bone marrow cells from congenic WBB6F1-+/+ causes an increase in MCps in the peritoneal cavity and that these progenitors differentiate into morphologically identifiable mast cells. The intraperitoneal injection of bone marrow-cultured mast cells before reconstitution significantly inhibited recruitment to and differentiation of MCps in the peritoneal cavity (Waki et al. 1990).

Only mast cell progenitor cells, not MCcps, were found in the blood stream and were responsible for populating peripheral tissues (Jamur et al. 2010). The mechanisms for homing or recruitment of progenitor mast cells to peripheral tissues during physiological and inflammatory states are not fully elucidated. The difficulties encountered in studying
this process lie with the low number of mast cell progenitors in the bone marrow or recruited to peripheral tissues as well as in the difficulty in identifying these cells. Also, the surface expression of chemoattractant receptors and adhesion molecules, which directly affect migration to target tissues, varies considerably according to maturation stage, target tissue, and cytokines and growth factors encountered in the microenvironment (Collington et al. 2011). Nevertheless, several studies from the past decade highlight the importance of some integrins, adhesion molecules, chemokines and their receptors, as well as cytokines and growth factors as important players in directed migration of mast cells to specific locations under normal and pathological circumstances (reviewed in Collington et al. 2011).

Mast cell progenitor migration seems to be controlled in a tissue-specific manner. Major progress has been achieved in clarifying mast cell progenitor migration to the small intestine and lungs. Mast cell progenitors are found in high numbers in the small intestine. The maintenance of mast cell numbers in the intestine occurs through constitutive homing that is contingent on the binding of α4β7 integrin, expressed on mast cells, with their corresponding adhesion molecules mucosal addressin cell adhesion molecule-1 (MAdCAM-1) or vascular cell adhesion molecule-1 (VCAM-1) on the endothelium (Gurish et al. 2001; Gurish and Boyce 2006). The enhanced recruitment of mast cells to the intestinal mucosa during *T. spiralis* infection was also dependent on the β7 integrin subunit expressed on mast cell progenitors (Artis et al. 2000; Pennock and Grencis 2004). Furthermore, CXC chemokine receptor 2 (CXCR2), expressed on mast cell progenitors, has been implicated in the directed migration of mast cells to the small intestine (Abonia et al. 2005).

Under physiological conditions, the lung does not have a significant number of mast cell progenitors, but their numbers increase considerably during chronic allergen-induced pulmonary inflammation when mast cell progenitors are actively recruited to the site of inflammation (Ikeda et al. 2003). This recruitment occurs through the interaction between α4β7 and α4β1 integrins expressed on mast cell progenitors with VCAM-1 and CXCR2 present on the endothelium. An amplification loop, regulated by CXCR2, can cause increased expression of VCAM-1 on the endothelium, which results in an increased integrin-mediated recruitment to the lung (Abonia et al. 2006; Hallgren et al. 2007). Additionally, it has been demonstrated that the chemokine (C-C motif) receptor 2 (CCR2)/chemokine (C-C motif) ligand 2 (CCL2) axis is active during recruitment of mast cell progenitors to inflamed lungs (Collington et al. 2010).

The involvement of integrins in the targeting of mast cells to the peritoneal cavity has also been described. Mac-1, a β2 integrin important for leukocyte migration, has been shown to be required for maintenance of mast cell levels in the peritoneal cavity, peritoneal wall, and certain regions of the skin. Mast cell recruitment to the peritoneal cavity in response to rat recombinant (rr)IL-3 was significantly inhibited by a prior intraperitoneal injection of antibodies against the integrin subunits α4 and β7 (de Cásia Campos et al. 2014). The αⅣβ3 integrin has a role in the adhesion of BMMCs to different substrates and influences the homing of mast cell progenitors to the peritoneal cavity (Rosenkranz et al. 1998; Berlanga et al. 2005).

Because mast cells express several chemokine receptors, they are chemotactically responsive to various chemokines. In vitro studies have shown that mouse unstimulated BMMCs were chemotactically attracted to the chemokines monocyte chemotactic protein-1 (MCP-1 or CCL2) and Regulated upon Activation, Normal T Cell Expressed and Secreted (RANTES, also known as CCL5). In contrast, antigen-stimulated BMMCs migrated in response to MCP-1, RANTES, macrophage inflammatory protein-1α (MIP-1α or CCL3), and platelet factor-4 (PF4 or CXCL4) (Taub et al. 1995). Subcutaneous injection of RANTES induced an increase in the number of metachromatic mast cells in the dermis and the spleen of Wistar rats (de Cásia Campos et al. 2014). Although, mast cells express several chemokine receptors and many chemokines have been shown to be chemoattractants for mast cells in vitro, no mast cell-specific chemokine has been described (Taub et al. 1995; Collington et al. 2011).

Mature mast cells and their released mediators were also believed to promote increased recruitment of progenitors to an inflammatory site, thus contributing to mast cell hyperplasia as is often seen in the airways of allergic patients. In patients with severe asthma, chymase-positive mast cells were increased in small airway regions and correlated positively with lung function (Balzar et al. 2005). The lipid mediator leukotriene B4 (LTB4) was shown to be important in the recruitment of mast cell progenitors to inflamed tissues and the subcutaneous injection of LTB4 induced an increase in the number of metachromatic mast cells in both the dermis and the spleen of Wistar rats (Weller et al. 2005; de Cásia Campos et al. 2014). In addition, Transforming Growth Factor-β (TGF-β), also released by mast cells, was shown to be a potent chemoattractant for mast cells in vitro (Gruber et al. 1994; Olsson et al. 2000; Lindstedt et al. 2001; Olsson et al. 2001).

Given the importance of the widespread distribution and recruitment of mast cells, the elucidation of the mechanisms that tightly regulate organ-specific targeting of mast cell progenitors remains a crucial goal.

### Development and Maturation

Maturing mast cells can be divided into three distinct stages based on their size and number of granules. Using the mast cell-specific antibody mAb AA4, which recognizes two derivatives of the ganglioside GD1b, it was shown that...
connective tissue-type mast cells can be identified in all stages of maturation in rat bone marrow (Jamur et al. 2001). This study also demonstrated that mast cell maturation in rat bone marrow was similar to that previously seen in the peritoneal cavity (Jamur et al. 1986; Mendonca et al. 1986).

Much of the current knowledge on the factors affecting mast cell development and maturation has been gained by the culture of mouse BMMCs in vitro in the presence of growth factors. Initial studies used several types of conditioned media that contained unidentified growth factors that supported mast cell growth and development (Hasthorpe 1980; Nabel et al. 1981; Nagao et al. 1981; Razin et al. 1981; Schrader 1981; Tertian et al. 1981). Interleukin-3 (IL-3) was found to be one of the factors in the conditioned media that was responsible for mast cell survival, development, and maturation (Ihle et al. 1981; Lee et al. 1982; Ihle et al. 1983; Razin et al. 1984; Metcalf 1986). In addition, IL-3 favors the development of a mucosal mast cell phenotype in vitro (Nakahata et al. 1986). Although critical for the development of murine BBMCs in vitro, IL-3 is not essential for mast cell development in vivo. IL-3-deficient mice are not deficient in mast cells, but the development of mast cell hyperplasia in response to nematode infection is impaired (Lantz et al. 1998). The culture of murine bone marrow cells with IL-3 alone for 3 days yielded mast cells that expressed transcripts for FcεRI subunits, bound IgE, but had few, if any, granules. With time in culture, this population increased progressively in parallel with the expression of FcεRI and its transcripts (Thompson et al. 1990). In humans, IL-3 does not affect mast cell differentiation of bone marrow CD34+ progenitors (Shimizu et al. 2008). Nonetheless, IL-3 is valuable in growing human mast cells from cord blood progenitors, as these mast cells are known to express the IL-3 receptor during all developmental stages (Dahl et al. 2004).

SCF, the ligand for the CD117/c-Kit receptor, is essential for mast cell survival and development in vitro. SCF alone is able to support the development of mast cells from mouse bone marrow (Gurish et al. 1992). The culture of mouse bone marrow enriched for hematopoietic progenitors with SCF in combination with IL-3 resulted in the surface expression of FcεRI on mast cells and the initiation of secretory granule formation after 3 days of culture (Lantz and Huff 1995). In vivo, mouse strains bearing mutations in the genes for the c-Kit receptor (KitW/W-v and KitW-sh) or its ligand SCF (Sl/Sld), which are deficient in mast cells, corroborate the significance of SCF for mast cell survival and development (Huang et al. 1990; Kitamura 2000; Grimbaldeston et al. 2005). It has been shown in primates that SCF injection causes a reversible expansion of mast cells at many sites (Galli et al. 1993a). Research on SCF demonstrated that it promotes mast cell adhesion, migration, proliferation and survival (Irani et al. 1992; Lemura et al. 1994; Okayama and Kawakami 2006). Gain-of-function mutations of c-Kit, which lead to the constitutive activation of the c-Kit receptor, are associated with mastocytosis, a neoplastic disorder characterized by mast cell expansion and accumulation in humans (Orfao et al. 2007).

Phenotypic Heterogeneity and Regulation

Other growth factors and cytokines also influence mast cell development and maturation and consequently contribute to the mast cell phenotype. Thus, it is the microenvironment encountered by mast cells that ultimately determines their mature phenotype (Jamur and Oliver 2011). Accordingly, mast cells exhibit a high degree of heterogeneity and plasticity, as a direct consequence of their widespread location and the mediators or the pathogens with which they interact. Changes in phenotype can take place during virtually all stages of mast cell existence. Different subsets of mature mast cells have been described on the basis of their location and functional, structural, and biochemical characteristics. Two subtypes of mature mast cells have been described in rodents: mucosal mast cells (MMCs) and connective tissue mast cells (CTMCs) (Enerbäck 1966a; 1966b). In mouse, MMCs reside in the mucosal epithelium of the lung and gastrointestinal tract, and their protease content is characterized by the chymases mouse Mast Cell Proteases, mMCP-1 and mMCP-2, which are bound to chondroitin sulfate chains of serglycin proteoglycans, whereas CTMCs are found in the intestinal submucosa, peritoneum, and skin and contain the chymase mMCP-4, the tryptases mMCP-5 and mMCP-6, and carboxypeptidase A (mCPA) bound to heparin chains of serglycin proteoglycans (Yurt et al. 1977; Enerbäck et al. 1986; Metcalf et al. 1997; Welle 1997; Miller and Pemberton 2002; Pejler et al. 2010). MMCs and CTMCs also differ in their ability to secret histamine and lipid mediators. Upon activation, MMCs release small amounts of histamine and large quantities of cysteinyl leukotrienes, whereas CTMCs release higher levels of histamine and prostaglandin D2 (Heavey et al. 1988). Additionally, athymic nude mice are devoid of MMCs; hence, these cells were designated as T-cell-dependent mast cells (Ruitenberg and Elgersma 1976). It is important to note that the mouse protease phenotypes described above can vary considerably among mast cells found in different tissues, in different locations of the same tissue, in the same tissue of different animal strains and also in inflamed tissues (Stevens et al. 1994; Gurish et al. 1995; Friend et al. 1996; Xing et al. 2011).

Mature human mast cells were similarly divided in two large subsets based on their protease content. The mast cell tryptase/chymase (MC1c) subset of cells store tryptases, chymases, and carboxypeptidases in their granules, whereas MC6 contain only tryptases (Irani et al. 1986; Schwartz 2006; Pejler et al. 2010). In human mast cells, serglycin proteoglycans contain both heparin and chondroitin sulfate.
Mature MCTC from skin and lung, but not in mature MC T abl. 2010). Human mast cells also differ with respect to the asthmatic subjects and esophageal samples of patients with eosinophilic esophagitis (Abonia et al. 2010; Dougherty et al. 2010). Human mast cells also differ with respect to the expression of the receptor C5aR for the complement C5a. Mature MC T from skin and lung, but not in mature MC T from lung, express C5aR (Oskeritzian et al. 2005).

Mast cell phenotypic heterogeneity, reflected in their extensive range of sensitivity to activation, and the variations in stored and released mediators, underlies the array of responses mast cells are able to generate (Metcalfe et al. 1997; Galli et al. 2004b). During the lifetime of a mast cell, numerous factors can alter its phenotype and a combination of these changes can determine mast cell homeostatic or pathophysiological responses (Moon et al. 2010). Mature mast cells can quickly alter their staining characteristics as a result of changes in proteoglycan expression both in vitro and in vivo (Razin et al. 1982; Sonoda et al. 1984; Nakano et al. 1985; Levi-Schaffer et al. 1986; Sonoda et al. 1986; Otsu et al. 1987; Kanakura et al. 1988b). Trans-differentiation between mucosal and connective tissue phenotypes has also been demonstrated (Kitamura 1989). Mouse mast cells are able to reversibly alter not only their serglycin proteoglycans but also their protease profile in vivo (Fiend et al. 1998). The mast cell phenotypic profile can be shaped by the cytokine and growth factor milieu they encounter (Table 1). In rodents, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) and IL-3 induce histidine decarboxylase synthesis, which in turn leads to an increased histamine production (Schneider et al. 1987). IL-4 acts in concert with IL-3 to promote mast cell growth and survival (Tsujii et al. 1990; Rennick et al. 1995). IL-4 also inhibits the expression of CD117 and FcεRI in mouse BM-MCs (Ryan et al. 1998; Mirmont et al. 1999). On the other hand, IL-4 treatment of human cultured mast cells enhances cell maturation and survival, promotes the expression of FcεRI and chymase in MC s, and downregulates CD117 expression (Sillaber et al. 1991; Yanagida et al. 1995; Toru et al. 1996; Toru et al. 1998). In mouse MM-MCs, IL-4 in combination with SCF induces differentiation of CTMCs (Karimi et al. 1999). The addition of IL-4 to SCF-treated, isolated human intestinal mast cells promotes mast cell proliferation and alters the pro-inflammatory profile of cytokines through the induction of Th2 cytokines (IL-3, IL-5, and IL-13) and the down-regulation of IL-6 (Lorentz and Bischoff 2001). Using a mouse model of allergy, Oettgen et al. (Burton et al. 2013) also established that IL-4 signaling is required for the mast cell expansion observed in the gastrointestinal mucosa in response to allergen ingestion. IL-9 is another important growth factor both for mice and human mast cells (Hültner and Moeller 1990; Godfraind et al. 1998; Matsuzawa et al. 2003). Mice that overexpress this cytokine display increased infiltration of CTMCs and MMCs into the gut, trachea, and kidney (Godfraind et al. 1998). In rodent mast cells, IL-10 exposure inhibits the expression of FcεRI, IL-6, and CD117 (Marshall et al. 1996; Mirmont et al. 1999; Gillespie et al. 2004; Kennedy Norton et al. 2008) but induces the expression of mMCP-1, a serine protease preferentially expressed in mucosal mast cells of Trichinella spiralis-infected mice (Ghildyal et al. 1992b). rIL-10 can induce the expression of mMCP-2 in connective tissue-type MM-MCs, whereas rIL-3 attenuates rIL-10-induced expression of this gene in vitro (Ghildyal et al. 1992a). IL-10 in combination with SCF was also shown to increase mast cell proliferation both in vivo and in vitro (Thompson-Snipes et al. 1991; Rennick et al. 1995; Kennedy Norton et al. 2008). The combination of IL-3, IL-4 and IL-10 leads to apoptosis of mouse peritoneal mast cells and BM-MCs (Yeatan et al. 2000). IL-6 promotes mast cell growth and survival in the presence of SCF (Galli 1990; Yanagida et al. 1995; Saito et al. 1996; Ochi et al. 1999; Gyotoku et al. 2001). However, IL-6 negatively modulates SCF development of cord blood-derived (CD34+) human mast cells (Kinoshita et al. 1999). Moreover, IL-6 has been shown to support the development of splenic mast cells, protect mast cells from IL-4-induced apoptosis, and increase chymase and histamine expression in cord blood-derived human mast cells (Hu et al. 1997; Kinoshita et al. 1999; Oskeritzian et al. 1999). The addition of IL-33 to cultures of CD34+ human mast cell progenitors induced the earlier expression of tryptase whereas rIL-33 addition to mBM-MCs increased tryptase expression both at the mRNA and protein levels (Allakhverdi et al. 2007a; Kaieda et al. 2010). IL-13, IL-15, and IL-16 all induce mast cell proliferation when combined with other cytokines (Masuda et al. 2000; Masuda et al. 2001; Qi et al. 2002; Kaur et al. 2006; Hu et al. 2007). TGF-β induces the expression of the αE integrin subunit and mast cell proteases mMCP-1, -6, and -7 in BM-MCs (Miller et al. 1999; Wright et al. 2002; Funaba et al. 2005; Funaba et al. 2006). Other molecules involved in mast cell maturation include Nerve Growth Factor (NGF) and Neurotrophin-3 (NT-3). NGF increases the number of IL-3-derived BM-MCs and induces a CTMC phenotype marked by increased histamine content and the expression of heparin (Matsuda et al. 1991). NGF also prevents apoptosis of murine peritoneal mast cells (Kawamoto et al. 1995). NT-3 promotes maturation of fetal mouse skin mast cells and human intestinal mast cells (Metz et al. 2004; Lorentz et al. 2007). The factors and phenotypic consequences affecting mast cells presented above are only a summary of the research published in this area.

In addition to changes affecting the microenvironment, mast cell phenotype is also dictated by animal species and...
New Insights into Mast Cell Function

Table 1. Mast Cell Phenotypic Regulation.

| Cytokines/Growth Factors | Mast Cell Type/Origin | Induced Mast Cell Phenotype | References |
|--------------------------|----------------------|-----------------------------|------------|
| GM-CSF, IL-3             | Isolated mouse BMCC progenitors | ↑ Histamine production | (Schneider et al. 1987) |
| IL-4+IL-3                | CTMCs purified from mouse peritoneal MCs | ↑ Growth and survival | (Tsuji et al. 1990) |
| IL-4, IL-10              | Mouse mesenteric lymph node derived MCs | ↑ SCF dependent mast cell growth and differentiation / ↑ Histamine production | (Rennick et al. 1995) |
| IL-4                     | Mouse BMCCs          | ↓ Expression of CD117 and FcεRI | (Ryan et al. 1998; Mirmonsef et al. 1999) |
| IL-4                     | Human cultured MCs   | ↑ Maturation, survival and expression of chymase and FcεRI / ↓ Expression of CD117 | (Sillaber et al. 1991; Yanagida et al. 1995; Toru et al. 1996; Toru et al. 1998) |
| IL4+SCF                  | Mouse BMCCs          | ↑ Proliferation and Th2 cytokine production (IL-3, IL-5, and IL-13) / ↓ IL-6 | (Karimi et al. 1999) |
| IL-9                     | Mouse CTMCs and MMCs | ↑ Proliferation and responsiveness to activation | (Hültner and Moeller 1990; Matsuzawa et al. 2003) |
| IL-9                     | Mouse CTMCs and MMCs | ↑ Intraepithelial infiltration of CTMCs and MMCs in the gut, trachea, and kidneys | (Godfraind et al. 1998) |
| IL-10                    | Mouse BMCCs, rat peritoneal MCs, and human skin-derived MCs | ↓ Expression of CD117, IL-6, and FcεRI / ↑ Expression of mMCP1 and mMCP2 / ↑ SCF dependent proliferation | (Thompson-Snipes et al. 1991; Ghildyal et al. 1992a; Ghildyal et al. 1992b; Rennick et al. 1995; Marshall et al. 1996; Gillespie et al. 2004; Kennedy Norton et al. 2008) |
| IL-3+IL-4+IL-10          | Mouse peritoneal and BMCCs | ↑ Apoptosis | (Yeatman et al. 2000) |
| IL-6+SCF                 | Human cultured MCs, mouse BMCCs | ↑ Growth and survival | (Yanagida et al. 1995; Saito et al. 1996; Ochi et al. 1999; Gyotoku et al. 2001) |
| IL-6                     | Human CD34(+) cord blood derived MCs | ↓ SCF-dependent development / ↑ Expression of chymase and histamine production | (Kinoshita et al. 1999) |
| IL-33                    | Human peripheral blood- or cord blood-derived CD34(+) progenitor cells and mouse BMCCs | Earlier expression of tryptase / ↑ Expression of mMCP-6 | (Allakhverdi et al. 2007a; Kaieda et al. 2010) |
| TGF-β                    | Mouse BMCCs          | ↑ Expression of αE integrin subunit, MCP-1, MCP-6, and MCP-7 | (Miller et al. 1999; Wright et al. 2002; Funaba et al. 2005; Funaba et al. 2006) |
| NGF                      | Mouse BMCCs and peritoneal MCs | ↑ Maturation, histamine content and heparin expression / ↓ Apoptosis | (Matsuda et al. 1991; Kawamoto et al. 1995) |
| NT-3                     | Fetal mouse skin MCs and human intestinal MCs | ↑ Maturation | (Metz et al. 2004; Lorentz et al. 2007) |

Abbreviations: BMCC, bone marrow mast cell; CTMC, connective tissue mast cell; GM-CSF, granulocyte macrophage colony-stimulating factor; IL, interleukin; MCs, mast cells; MMC, mucosal mast cell; mMCP, mouse mast cell protease; NGF, nerve growth factor; NT-3, neurotrophin-3; SCF, stem cell factor; TGF-β, transforming growth factor-β.

genetic background (Galli et al. 2011). The relevance of most of the in vitro findings on the influence of cytokines and growth factors on mast cell phenotype has yet to be confirmed in vivo. However, it is evident that mast cell heterogeneity in peripheral tissues encompasses a far more diverse and dynamic profile than the two mast cell subsets
Mast cells store an extensive variety of preformed mediators and receptor involved (Galli and Lantz 1999). Activation can lead to release of three distinct classes of mediators: preformed mediators, which are stored in mast cell cytoplasmic granules; neoformed or lipid mediators, which are derived from membrane lipids; and neosynthesized mediators, which are produced following transcriptional activation and whose regulation depends on the type of stimuli (Rothschild and Schayer 1959; Ringvall et al. 2008).

Mast cell functions reflect their ability to secrete a diverse array of biologically active compounds (Table 2). Mast cell activation culminates with the release of a wide range of inflammatory mediators (Metcalfe et al. 1997). Activation of mast cells can lead to release of three distinct classes of mediators: preformed mediators, which are stored in mast cell cytoplasmic granules; neoformed or lipid mediators, which are derived from membrane lipids; and neosynthesized mediators, which are produced following transcriptional activation and whose regulation depends on the type of stimuli and receptor involved (Galli and Lantz 1999).

**Preformed mediators.** Mast cells store an extensive variety of preformed mediators in their secretory granules. Ehrlich first described mast cells as granular connective tissue cells and emphasized the presence of a yet unknown substance bound to granular storages in the protoplasm, which reacted with basic aniline dyes giving a typical metacromasia (Ehrlich 1878). It is now known that the metachromatic properties of mast cells are due to the interaction of basic (cationic) dyes with acidic (anionic) residues on highly sulfated glycosaminoglycan (GAG) chains (heparin and/or chondroitin sulfate) attached to the proteoglycan serglycin, the major constituent of mast cell granules (Jorpes 1935; Holmgren 1937; Ranson and Gallagher 1992; Abrink et al. 2004). Serglycin is a proteoglycan expressed in hematopoietic cells and endothelial cells. Its core protein consists of 153 amino acids with 24 serine-glycine repeats between amino acids 89 and 137 (Pejler et al. 2009). The main function of serglycin is to regulate storage of several compounds present in hematopoietic cells. Negatively charged GAG chains concentrate proteases, histamine, and other positively charged molecules within the granule (Melo et al. 2011).

Histamine is the best known biogenic amine and was one of the first functionally active mast cell mediators to be described (Rocha e Silva, 1947; Riley and West 1952). Histamine synthesis occurs through decarboxylation of histidine by the enzyme histidine decarboxylase, which is expressed in increasing amounts during mast cell maturation (Rothschild and Schayer 1959; Ringvall et al. 2008). Among the various effects of histamine are vasodilation, bronchoconstriction, increased capillary permeability, and smooth muscle contraction, all of which are commonly associated with allergic and inflammatory reactions (Lundequist and Pejler 2011). Research using knockout animals for the histidine decarboxylase (HDC) gene also described a role for histamine in various pathological conditions such as autoimmune diseases, anaphylaxis, and atherosclerosis (Makabe-Kobayashi et al. 2002; Sasaguri et al. 2005; Musio et al. 2006; Ohtsu 2008). More importantly, it was recently shown that histamine is implicated in the regulation of dendritic cell (DC) functions (Simon et al. 2011).

Serotonin is another biogenic amine present in rodent mast cell granules (Benditt et al. 1955). The presence of serotonin in human mast cells was demonstrated in human peripheral blood, where its levels are elevated in patients with mastocytosis (Kushnir-Sukhov et al. 2007).

Although bovine mast cells are known to contain dopamine (Edvinsson et al. 1977), it has been only recently that the storage of dopamine in rodent mast cells has been confirmed (Freeman et al. 2001; Rönnberg et al. 2011).

Mast cell granules exhibit several similarities to lysosomes, among which are low pH and the presence of several lysosomal enzymes. β-hexosaminidase is the best characterized of these enzymes and is ubiquitous to all mast cell subtypes in all species. Quantification of the released β-hexosaminidase activity is often used as a measure of mast cell degranulation (Lundequist and Pejler 2011). In addition, viable mast cells were found to store and secrete enzymatically active caspase-3 (Garcia-Faroldi et al. 2013).

Mast cell proteases are stored within mast cell granules as active enzymes and constitute approximately 25% of mast cell protein content (Schwartz and Bradford 1986; Schwartz et al. 1987; Huang et al. 2000). Chymases, tryptases, and carboxypeptidase A are exclusively expressed by mast cells. They have been implicated in several pathological states including arthritis, allergic airway inflammation, tumor angiogenesis, innate immune defense, glomerulonephritis, and abdominal aortic aneurism formation (McNeil et al. 2008; Shin et al. 2008; Sun et al. 2009; Waern et al. 2009; Scanduzzi et al. 2010; Souza-Junior et al. 2011). Chymases can contribute to ECM remodeling both directly, through cleavage of fibronectin and non-helical collagens, and indirectly, through activation of matrix metalloproteinases (MMPs), which are also released upon mast cell activation (Fang et al. 1996; Tchougounova et al. 2005; Caughey 2007). Mast cell proteases have also been shown to play a modulatory role in the course of allergic reactions. β-Tryptase acts to limit allergic inflammation through the cleavage of IgE after being released by activated mast cells (Rauter et al. 2008).

The ability of mast cells to store cytokines within their granules was first demonstrated for tumor necrosis factor-alpha (TNF-α) (Gordon and Galli 1990). Currently, several studies suggest that numerous cytokines and growth factors are stored in mast cell granules along with other preformed mediators (Grützkau et al. 1997; Sayed et al. 2008; Lundequist and Pejler 2011).

Recently, in addition to the well-known mast cell preformed mediators, several other preformed mediators have...
New Insights into Mast Cell Function

been described (Table 2). These mediators exhibit distinct functions in diverse circumstances where mast cells are involved. It is important to keep in mind that the specific profile of preformed mediators varies considerably according to the species, subtype, and surrounding microenvironment where mast cells are found.

Mast cell granule contents are released through degranulation, which involves fusion of membrane granules with the plasma membrane and extrusion of membrane-free granule content into the external environment. Mast cells are unique among hematopoietic cells in that they are able to re-granulate and remain functional after degranulation.

Table 2. Mast Cell Mediators.

| MEDIATORS                  | REFERENCES                     |
|----------------------------|--------------------------------|
| **PREFORMED**              | (Lundequist and Pejler 2011)   |
| Biogenic Amines            |                                |
| Histamine, Serotonin (5-HT), Dopamine, Polyamines | (Ohtsu 2008; Kanerva et al. 2009; Garcia-Faroldi et al. 2010; Ronnberg et al. 2011) |
| Lysosomal Enzymes          |                                |
| β-hexosaminidase, β-glucuronidase, β-D-galactosidase, Arylsulphatase A, Cathepsins C, B, L, D, and E | (Schwartz and Austen 1980; Schwartz et al. 1981; Dragonetti et al. 2000; Wolters et al. 2000; Henningsson et al. 2005) |
| Proteases                  |                                |
| Chymase, Trypsate, Carboxypeptidase A, Cathepsin G, Granzyme B, Matrix metalloproteinases, and Renin | (Parikh et al. 2003; Silver et al. 2004; Reid et al. 2007; Maxová et al. 2010; Pejler et al. 2010; Trivedi and Caughey 2010; Caughey 2011) |
| Other Enzymes              |                                |
| Kinogenases, Heparanase, Angiogenin and Active Caspase-3 | (Bashkin et al. 1990; Kulka et al. 2009; Lilla et al. 2009; Garcia-Faroldi et al. 2013) |
| Proteoglycans              |                                |
| Serglycin (Heparin and Chondroitin sulphate) | (Yurt et al. 1977; Metcalfe et al. 1979; Enerbäck et al. 1985; Thompson et al. 1988; Abrik et al. 2004; Pejler et al. 2009; Melo et al. 2011; Ronnberg and Pejler 2012) |
| Cytokines                  |                                |
| TNF-α, IL-4, IL-15         |                                |
| Chemokines                 |                                |
| RANTES (CCL5), eotaxin (CCL11), IL-8 (CXCL8), MCP-1 (CCL2), MCP-3 (CCL7), MCP-4 | (Gibbs et al. 2001; Collington et al. 2010; Collington et al. 2011) |
| Growth Factors             |                                |
| TGF-β, bFGF-2, VEGF, NGF, SCF | (Gordon and Galli 1990; Leon et al. 1994; Boesiger et al. 1998; Grützkau et al. 1998; Qu et al. 1998; Dvorak et al. 2001; Lindstedt et al. 2001; Alakhrveldi et al. 2007a) |
| Peptides                   |                                |
| Corticotropin-Releasing Hormone, Endorphin, Endothelin-I, IL-37/Cathelicidin, Substance P, Vasoactive Intestinal Peptide | (DiAugustine et al. 1980; Ehrenreich et al. 1992; Gulubova and Vodenicharov 2001; Di Nardo et al. 2003; Kumpuraj et al. 2004; Hultner and Ehrenreich, 2005; Di Nardo et al. 2008; Pongor et al. 2011) |
| Others                     |                                |
| Eosinophil Major Basic Protein (MBP) | (Butterfield et al. 1990) |
| **NEOFORMED**              |                                |
| Phospholipid Metabolites   |                                |
| Prostaglandin D2, E2, Leukotrienes B4, C4, and Platelet Activating Factor | (Boyce 2005) |
| **NEOSYNTHESIZED**         |                                |
| Cytokines                  |                                |
| IL-33, IL-10, IL-12, IL-17, IL-5, IL-13, IL-1, IL-2, IL-3, IL-4, IL-6, IL-8, IL-9, IL-16, Type I and Type II IFN, TNF-α, MIP-2β | (Gordon and Galli 1990; Rubinchik et al. 1995; Williams and Coleman 1995; Rumsaeng et al. 1997; Ackerman et al. 1999; Masuda et al. 2000; Supajatara et al. 2001; Masuda et al. 2002; Okayama et al. 2003; Gessner et al. 2005; Kohn et al. 2005; Nakano et al. 2007; Nigrovic et al. 2007; Stassen et al. 2007; Buckland 2010; Dietrich et al. 2010; Hsu et al. 2010; Oldford et al. 2010; Lin et al. 2011; Nam et al. 2011) |
| Growth Factors             |                                |
| SCF, GM-CSF, β-FGF, NGF, PDGF, TGF-β, VEGF | (Wodnar-Filipowicz et al. 1989; Leon et al. 1994; Reed et al. 1995; Grützkau et al. 1998; Zhang et al. 1998; Aceves et al. 2010; van Steensel et al. 2012) |
| Reactive Oxygen Species    |                                |
| Nitric Oxide               | (Swindle and Metcalfe 2007; Endo et al. 2011) |
| Others                     |                                |
| Complement Factor C3 and C5 | (Fukuoka et al. 2013) |

Abbreviations: FGF, fibroblast growth factor; GM-CSF, granulocyte macrophage colony-stimulating factor; IL, interleukin; MCP, monocyte chemotactic protein; NGF, nerve growth factor; PDGF, platelet-derived growth factor; RANTES, regulated upon activation, normal T cell expressed and secreted; SCF, stem cell factor; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-alpha; VEGF, vascular endothelial growth factor; MIP-2β, macrophage inflammatory protein-2β;
Neuroformed mediators. Increased levels of intracellular calcium and mitogen-activated protein kinase (MAPK) phosphorylation in activated mast cells leads to the rapid production and release of neuroformed mediators, known as eicosanoids. Eicosanoids are produced through the catalytic conversion of arachidonic acid, which is released through the enzymatic action of phospholipase A2 (PLA2) on membrane phospholipids (Clark et al. 1991; Berenbaum et al. 2003). Arachidonic acid is converted into the intermediary molecule prostaglandin H2 (PGH2) by the action of cyclooxygenases (COX). Mast cells express both the constitutive (COX-1) and inducible (COX-2) forms of this enzyme (Murakami et al. 1994). PGH2 is the bioactive precursor of all prostaglandins and conversion to PGD2, the most important prostaglandin in mast cells, is dependent on the enzyme PGD2 synthase (Peters et al. 1984; Urade et al. 1990). Synthesized PGD2 is released through a prostaglandin transporter protein (Lu et al. 1996) and acts through the specific G protein-coupled receptors (GPCRs), PD1 and PD2s (Boie et al. 1995; Hirai et al. 2001). Prostaglandins contribute to increased vascular permeability, leukocyte recruitment, mucus production, and nerve cell activation (Galli et al. 2003a; Weller et al. 2007).

Leukotriene production in mast cells requires the reversible translocation of the enzyme 5-lipoxygenase (5-LO) to the perinuclear region (Malaviya and Jakschik 1993). 5-LO and the five lipoxygenase activator protein (FLAP) sequentially convert arachidonic acid into the unstable intermediates 5-Hydroperoxyeicosatetraenoic acid (5-HpETE) and leukotriene A4 (LTA4) (Dixon et al. 1990). LTA4 is subsequently converted to leukotriene B4 (LTB4) by the LTA4 hydrolase (Evans et al. 1985) or undergoes conjugation to reduced glutathione to form leukotriene C4 (LTC4) by LTC4 synthase (LTC4S), which is the precursor for all cysteinyl leukotrienes (cysLT) (Lam et al. 1994). LTC4, the most relevant leukotriene in mast cells, is released through an energy-dependent export mechanism involving the multidrug resistance protein, MRP-1 (Peters et al. 1984; Leier et al. 1994). Similar to PGD2, cysLTs also bind and activate two GPCRs, CysLT1 and CysLT2. LTB4 is secreted in small quantities by activated mast cells and has an important role in the recruitment of neutrophils, eosinophils, and effector T lymphocytes (Goodarzi et al. 2003; Caros et al. 2011). Leukotrienes function locally on the vascular endothelium by promoting rolling and recruitment of neutrophils and eosinophils, which contribute to host defense against bacterial infections (Malaviya and Abraham 2000; Caros et al. 2011). In general, mast cell-released eicosanoids participate in the regulation of vascular permeability, smooth muscle contraction, the recruitment of immune effector cells, and they alter the patterns of antigen presentation (Boyce 2005).

Neosynthesized mediators. Neosynthesized mediators are synthesized after transcriptional activation as the result of mast cell activation. Their regulation depends on the type of stimuli as well as the specific receptor involved in the activation. These mediators include cytokines and chemokines, which are released hours after activation. Mast cells synthesize and release both proinflammatory and anti-inflammatory cytokines. Anti-inflammatory cytokines comprise TGF-β and IL-10. Proinflammatory cytokines include cytokines associated with type 2 T-helper cell (Th2) responses such as IL-4, IL-5, IL-6, and IL-1 and cytokines associated with Th1 responses including interferon-gamma (IFN-γ), IL-2, IL-3, IL-12, IL-18, and TNF-α. The chemokines CCL5 and CXCL8 are also synthesized by mast cells and recruit immune cells to sites of infection (Marshall, 2004). Other chemokines produced by murine mast cells are MIP-1α (CCL3), MIP-1β (CCL4), and MCP-1 (CCL2) which help to perpetuate inflammation (Burd et al. 1989).

Mast Cell Activation

Mast cells may be activated by several distinct stimuli acting on numerous receptors on the mast cell surface. The range and nature of mast cell responses to different stimuli can be influenced by intrinsic and microenvironmental factors that affect the expression or functionality of surface receptors and/or signaling molecules that contribute to these responses (Galli et al. 2005b; Metcalfe et al. 2009).

The most studied method of mast cell activation is the allergic reaction, an adaptive immune response mediated by the high affinity IgE receptor on the mast cell surface (Galli et al. 2005a). Currently, the innate immune regulation of mast cell activation has become center stage. As an innate immune cell, mast cells are equipped for early and rapid sensing of invading microorganisms such as bacteria, parasites, fungi, and viruses. These pathogens display conserved molecular structures called pathogen-associated molecular patterns (PAMPs), which are recognized by pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), on the mast cell surface. The direct interaction between specific PAMPs and PRRs induces mast cell activation and selective mediator release (Marshall 2004). In addition, mast cells can be activated by several other stimuli such as neuropeptides, cytokines, growth factors, toxins, basic compounds, complement, immune complexes, certain drugs, as well as physical stimuli (Tkaczyk et al. 2004a; Gilfillan et al. 2009). Certain lectins are able to activate mast cells and promote mediator release, largely through crosslinking IgE or FcεRI on the mast cell surface (Wyczolkowska et al. 1992; Moreno et al. 2003; de Almeida Buranello et al. 2010).
Recent research has showed that receptors for numerous ligands, including adenosine, C3A, immune complexes, chemokines, cytokines, PAMPs, sphingosine-1-phosphate (S1P), and SCF, are involved in mast cell activation. These receptors are able to potentiate FcεRI-mediated activation or to directly stimulate mediator release in an FcεRI-independent manner. The modulation of the signaling pathways mediated by these receptors accounts for the fact that different stimuli can lead to diverse combinations of mediators being released through the differential induction of degranulation, eicosanoid and cytokine production and release (Gilfillan and Tkaczyk 2006). Although, the early events of the signaling cascades initiated by these receptors are different, they converge downstream in order to provide the necessary signals for mediator release (Gilfillan and Tkaczyk 2006).

**FcεRI-mediated mast cell activation.** Allergy is the most recognized consequence of mast cell inflammatory mediator release. Type I allergic reactions are the hallmark of these cells and are mediated through FcεRI, which is highly expressed on the mast cell surface and positively regulated by increased IgE concentrations (Yamaguchi et al. 1997; Kawakami and Galli 2002). FcεRI belongs to the immunoglobulin receptor superfamily and is expressed as a heterotetramer formed by the subunits αβγ2, . The α subunit possess an extracellular domain that binds to the Fc portion of IgE, whereas the β and γ subunits carry immunoreceptor tyrosine-based activation motifs (ITAMs) on their cytoplasmic portions. FcεRI-mediated activation is the most studied and best characterized pathway for mast cell activation (Galli et al. 2005a). The activation process is contingent on antigen-specific IgE, produced by B lymphocytes after antigen presentation and IL-4 stimulation (Kinetic 1999). Binding of multivalent antigens recognized by IgE, previously bound to FcεRI on the mast cell surface, promotes receptor cross-linking and translocation into lipid rafts followed by a cascade of intracellular signaling events (Metzger 1992; Kovárová et al. 2001; Siraganian 2003). FcεRI signaling relies on Lyn-dependent phosphorylation of ITAMs on the cytoplasmic portion of the β and γ receptor subunits. The protein kinase Syk is recruited to the phosphorylated ITAMs where it becomes activated and autoprophosphorylated (Zhang et al. 2000; de Castro et al. 2010). Subsequently, Syk phosphorylates adaptor proteins, such as linker of activation of T cells (LAT) and non-T cell activation linker (NTAL), which serve as platforms for various other signaling molecules. LAT-dependent activation of phospholipase C (PLC) produces inositol triphosphate (IP₃) and diacylglycerol (DAG), which in turn cause intracellular calcium influx and protein kinase C (PKC) activation. NTAL activation leads to phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) activation, which also contributes to calcium mobilization (Gilfillan and Tkaczyk 2006). In summary, this signaling cascade comprises four major cellular events, namely protein phosphorylation, lipid metabolism and phosphorylation, intracellular calcium mobilization, and transcription factor activation (Benhamou and Siraganian 1992; Choi et al. 1996; Liou et al. 2005; Tkaczyk et al. 2006). The final events of this signaling cascade culminate in degranulation, lipid mediator production, and cytokine production (Ozawa et al. 1993; Razin et al. 1994; Gilfillan 1997; Metcalfe et al. 1997; Ali et al. 2004; Cho et al. 2004). In the later stages of mast cell activation, serine and threonine kinases belonging to the PKC and MAPK families play a predominant role. The calcium signaling promoted by PLCγ and PI3K is essential for several signaling events including activation of phospholipase D (PLD), PLA2, calcium-dependent PKC isoforms and for the regulation of the nuclear factor of activated T cells (NFAT) transcription factor through calcium binding proteins such as calmodulin and calcineurin (Kumada et al. 1995; Ishimoto et al. 1996; Cho et al. 2004).

The calcium-dependent PKC isoforms β and ε regulate the production of the transcription factors Fos and Jun and the consequent cytokine production (Razin et al. 1994). The MAPks extracellular signal-regulated kinases (ERK1, 2, and 5), p38, and c-Jun N-terminal kinase (JNK) act to regulate the phosphorylation of specific transcription factors and therefore are important for the production of cytokines and chemokines by activated mast cells. Moreover, ERK1/2 regulates PLA2 activation and eicosanoid production upon FcεRI crosslinking (Siraganian 2003). Transcriptional regulation by specific transcription factors in response to FcεRI activation is contingent on MAPks, PKC, PI3K, and elevated calcium levels (Ishizuka et al. 1999; Hundley et al. 2004; Qiao et al. 2006). Transcription factors, such as nuclear factor-kappa B (NFκB), NFAT, activating transcription factor 2 (ATF-2), and components of the activating protein-1 (AP-1) (Fos and Jun) bind to multiple binding sites in the promoter regions of cytokine genes to regulate their expression (Pelletier et al. 1998; Marquardt and Walker 2000; Shaulian and Karin, 2002; Lorentz et al. 2003).

**Pathogen-mediated mast cell activation.** The initial recognition of microorganisms is mediated by a series of PRRs such as TLRs, nod-like receptors (NLRs), and retinoic acid-inducible gene 1 (RIG-1)-like receptors (RLRs), expressed on various immune cells, including mast cells. These receptors are part of a family of cytosolic and membrane receptors that collectively recognize danger signals and PAMPs. Mast cells express the TLRs 1-7 and 9, and the stimulation of specific receptors by different pathogens induces different mast cell responses.

TLR stimulation promotes the association of the adaptor proteins myeloid differentiation primary response gene 88 (MyD88) and MyD88 adaptor-like/Toll interleukin-1 receptor (MAL/TIRAP). MyD88 recruits a complex formed by interleukin-1 receptor-associated kinases (IRAKs) and TNF-
receptor-associated factor 6 (TRAF6), which is dissociated to form a new complex with TGF-β-activated kinase 1 (TAK1) and TAK1 binding protein (TAB). TRAF6 activates TAK1 and, together with TAB, activate the IKK kinase (IKK) complex, thereby promoting NFXB nuclear translocation and cytokine transcription (Cook et al. 2004). TLR signaling also includes MyD88-independent pathways that rely on the adaptor molecules TIR-domain-containing adapter-inducing interferon-β (TRIF) and TLR adaptor molecule (TRAM) (Basu and Fenton 2004; Cook et al. 2004). MyD88-dependent and -independent signaling pathways culminate in similar signaling cascades that promote the activation of PI3K, MAPKs, and transcription factors.

TLR4 stimulation by lipopolysaccharide (LPS) promotes cytokine production without induction of degranulation. On the other hand, TLR2 stimulation by peptidoglycan induces both degranulation and cytokine production by mast cells (Supajutra et al. 2002). Double-stranded RNA (dsRNA) stimulates TLR3 on the mast cell surface and induces the production of antiviral cytokines such as TNF-α and IFN-β, without mast cell degranulation (Orinska et al. 2005). Mast cells also express cytoplasmic RLRs such as RIG-I, protein kinase RNA-activated (PKR), and melanoma differentiation-associated gene 5 (MDA-5), which recognize viral and synthetic dsRNA and evoke mast cell activation and antiviral cytokine and chemokine production without degranulation (Fukuda et al. 2013; Graham et al. 2013).

**Complementary receptors.** The mast cell microenvironment includes a multitude of factors that can modify mast cell activation. Mast cells express a variety of receptors that, if activated, can alter the production and release of mediators (Giffiilan and Tkaczyk 2006; Kuehn and Giffiilan 2007).

Mast cells can be positively or negatively regulated by IgG multimeric receptors (FcγR) (Tkaczyk et al. 2004b). These receptors enable mast cells to participate in humoral defense but also endow mast cells with the capacity to act in antibody-induced pathologies (Nigrovic and Lee 2005). The FcγRI IgG receptor belongs to the same immunoglobulin receptor superfamily as FcεRI. FcγRI and FcγRIII IgG receptors share a common ITAM-containing γ subunit with FcεRI; hence they can be activated in a similar fashion and exhibit similar signaling pathways (Daëron et al. 1992; Falanga et al. 2012). FcγRI is not constitutively expressed in human and rodent mast cells, but small concentrations of IFN-γ induce mast cell expression of FcγRI in human mast cells (Okayama et al. 2000). Aggregation of IgG1 bound to FcγRI induces a similar pattern of mediator release as FcεRI activation (Okayama et al. 2000; Okayama et al. 2001a).

The low affinity IgG receptors FcγRIIb and FcγRIII are also present on the mast cell surface (Okayama et al. 2001b). FcγRIII is predominantly expressed in mast cells of the serosal type and its expression in IL-3-derived BMMCs, which display a mucosal phenotype, can be induced by SCF (Katz and Lobell 1995). Crosslinking of FcγRIII by IgG immune complexes induces mast cell degranulation and the subsequent generation of several lipid mediators (Katz et al. 1990; Katz et al. 1992). In contrast to FcεRI and FcγRIII, which activate mast cells in a similar way as FcεRI, FcγRIIB receptors, as well as mast cell function-associated antigen (MAFA), myeloid-associated immunoglobulin-like receptor I and II (MAIR), paired immunoglobulin-like receptor B (PIRB), sialic acid binding Ig-like lectin 8 (sigglec-8), CD200R, CD300a, and CD300f receptors, are expressed by mast cells and, when ligated or coligated with FcεRI, they exert an inhibitory action (Uehara et al. 2001; Abramson et al. 2002; Yotsumoto et al. 2003; Cherwinski et al. 2005; Alvarez-Errico et al. 2007; Daëron et al. 2008; Bochner 2009). These receptors are monomeric transmembrane proteins that contain one IgG or lectin C in their extracellular portion and, with the exception of CD200R, they bear one or more immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their cytosolic domains (Daëron et al. 2008; Karra et al. 2009). FcγRIIB is unique among Fc receptors in that it is the only one to exhibit an inhibitory action. Aggregation of ITIM-containing receptors is not sufficient to promote ITIM phosphorylation. Co-aggregation with ITAM-containing receptors is necessary for the activation of Src kinases. Activation of the Src kinases leads to phosphorylation of ITAMs, which in turn will phosphorylate the inhibitory ITIM (Malbec et al. 1998). ITIM phosphorylation allows for the recruitment of cytosolic phosphatases with Src2 homology domains (SH2), such as SHIP1 and SHIP2. These phosphatases dephosphorylate tyrosine residues that are necessary for the binding of signaling kinases, hence suppressing signaling and mediator release (Shik and Munitz 2010). Inhibitory receptors have been given increased attention because they are potential therapeutic targets for diseases involving excessive mast cell activation (Daëron 1995; Ott and Cambier 2000; Malbec and Daëron 2007; Guiraldelli et al. 2008).

The c-Kit receptor (CD117), the receptor for SCF, is crucial for mast cell survival, differentiation, and maturation. Unlike FcεRI, c-Kit is composed of a single transmembrane protein and has intrinsic kinase activity (Linnekin 1999). c-Kit receptor dimerization, caused by SCF, induces the auto-phosphorylation of various tyrosine residues in the cytoplasmic tail of c-Kit, which, in turn, induces the recruitment of cytosolic adaptor proteins, kinases, and signaling enzymes. The subsequent activation of these enzymes, along with janus kinase-signal transducer and activator of transcription (JAK-STAT) and RAS-RAF-MAPK pathways, leads to growth, differentiation, survival, chemotaxis, and mast cell cytokine production. There are only a few reports indicating that SCF binding to c-Kit induces mast cell degranulation (Coleman et al. 1993; Galli et al. 1993b). Nonetheless, SCF binding to c-Kit can potentiate antigen-induced mast cell degranulation.
and cytokine production (Hill et al. 1996; Hundley et al. 2004; Tkaczyk et al. 2004a). This effect indicates an integration of the signaling pathways initiated by both receptors (Bischoff and Dahinden, 1992; Iwaki et al. 2005; Gilfillan and Tkaczyk 2006).

Mast cells also express receptors for several components of the complement system, for instance complement receptors (CRs) CR3, CR4 and CR5. In vitro studies showed that the products of the complement system, C3a and C5a, activate mast cells and also induce chemotactic activity (Nilsson et al. 1996). C3aR is a member of GPCR family and, when activated, induces degranulation and production of cytokines such as MCP-1 (CCL2) and RANTES (CCL5) in the human mast cell line, LAD2 (Venkatesha et al. 2005). In a manner to similar other GPCRs, such as adenosine 3, sphingosine 1 phosphate-2 (S1P2), C-C Chemokine Receptor type 1 (CCR1), corticotropin-releasing hormone receptor (CRHR), and the beta-adrenoceptor, complement receptors are able to modulate the basal and antigen-mediated mediator release (Tkaczyk et al. 2006).

**Physiological Functions of Mast Cells**

Mast cells have an immunomodulatory as well as a physiological function in the epithelium, endothelium, and nervous system. Their ubiquitous distribution places mast cells in a privileged position to act not only as guardians of the immune system, but to also participate in many biological processes and in the maintenance of homeostasis (Weller et al. 2011).

**Homeostasis and Tissue Repair**

Mast cells are considered crucial for the maintenance of tissue function and integrity (Maurer et al. 2003). Many mast cell mediators including NGF, platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and fibroblast growth factor-2 (FGF-2 or bFGF), as well as histamine and tryptase, induce epithelial cell and fibroblast proliferation (Abe et al. 2000). Furthermore, mast cells are involved in all steps of tissue repair, from the initial inflammatory reaction to extracellular matrix (ECM) remodeling (Noli and Miolo 2001). Upon injury, skin mast cells act at the very beginning to regulate primary hemostasis to seal the injured surface. Through the release of platelet activating factor (PAF), leukotrienes, and the cytokines IL-1 and IL-8, mast cells contribute to platelet activation and aggregation as well as extravascular deposition of fibrin (Mekori and Galli 1990; Kauhanen et al. 1998). Conversely, mast cells also secrete heparin, tryptase and t-plasminogen activator (tPA) thereby regulating fibrinolytic mechanisms providing the appropriate perfusion and nutrition necessary for repair (Huang et al. 1997; Gottwald et al. 1998; Thomas et al. 1998). As the inflammation proceeds, mast cells promote the recruitment of circulating leukocytes, which contribute to microbial clearance and debris removal (Rock et al. 1990; Kanwar and Kubes 1994). In the proliferation phase, mast cell mediators stimulate growth, migration and proliferation of endothelial cells, fibroblasts and keratinocytes thereby contributing to angiogenesis, collagen deposition, granulation tissue formation, epithelialization, and wound contraction (Levi-Schaffer and Kupietzky 1990; Katayama et al. 1992; Meininger and Zetter 1992; Moulin et al. 1998). The release of vasoactive amines, tryptase, IL-4, and NGF contribute to the regeneration of damaged nerve fibers (Matsuda et al. 1998; Schaffer et al. 1998). Proteolytic mediators released during mast cell degranulation influence not only the deposition of temporary connective matrix but also coordinate its replacement by a definitive connective tissue (Nishikori et al. 1998). In the late phases of repair, mast cell cytokines (IL-1, IL-4, and IL-6) and growth factors (FGF and TGF) influence the phenotype of activated fibroblasts inducing the appearance of myofibroblasts, which are important for contraction and wound healing (Hebda et al. 1993; Moulin 1995; Moulin et al. 1998).

Mast cells are also important in preserving the homeostasis of tissues and organs, which is characterized by continuous growth and remodeling, such as in hair follicles and bones. The mast cell mediators histamine, TNF, and substance P participate in tissue remodeling and help regulate the hair follicle growth cycle; mast cell-deficient mice have defects in this process (Maurer et al. 1995). Histamine promotes the recruitment and differentiation of osteoclast precursors during the initial stages of bone resorption (Lesclous et al. 2004; Fouilloux et al. 2006; Lesclous et al. 2006). Mast cell tryptase can specifically activate the protease-activated receptor-2 (PAR-2), which inhibits osteoclast differentiation (Smith et al. 2004). Similar to histamine, it is believed that IL-1, TGF-β, IL-6, and PDGF influence osteoclast recruitment and development, which in turn contribute to bone remodeling. Osteopontin (OPN), also released by mast cells, functions in the balance and maintenance of mineralization, thus contributing to the control of bone metabolism (Chiappetta and Gruber 2006; Bulfone-Paus and Paus 2008). OPN was found to stimulate degranulation and migration of mast cells in vitro and OPN (−/−) mice displayed reduced IgE-mediated passive cutaneous anaphylaxis (Nagasaka et al. 2008).

**Nervous System**

The distribution of mast cells around nerve endings in various tissues including skin, intestinal mucosa, lung, and the central nervous system has been described since Ehrlich. This mast cell localization and, more importantly, the mediators released by both mast cells and neurons collaborate in the establishment of a neuroimmune interaction between these cells. It has been shown that communication between mast cells and neurons can occur through synaptic-like structures sustained by adhesion molecules such as
N-cadherin or synaptic cell adhesion molecule (SynCAM) (Suzuki et al. 2004; Furuno et al. 2005). Mast cell-derived serotonin contributes to neurogenesis and to the behavioral and physiological function of the hippocampus (Nautiyal et al. 2012). Mast cell proteases, such as tryptase, signal nerves through PARs; PAR2 activation has been implicated in increased intestinal permeability and visceral hypersensitivity in rodents (Déry et al. 1998; Vergnolle et al. 2001; Coelho et al. 2002; Cenac et al. 2003). On the other hand, mast cells can be activated by substance P and endothelin-1 (ET-1) (Ogawa et al. 1999; Suzuki et al. 1999). Mast cell activation by ET-1, which is an endogenous peptide of considerable toxicity, causes mast cell degranulation with a consequent release of the mast cell-specific proteases such as chymases and CPA, which promote ET-1 degradation thus limiting its toxicity (Maurer et al. 2003; Galli and Tsai 2008). Mast cell-neuron interactions also contribute to the maintenance of intestinal homeostasis by regulating ion transport, vascular permeability, secretory activity of mucus producing cells, and gastrointestinal motility (Van Nassauw et al. 2007).

**Angiogenesis**

Angiogenesis is a dynamic process characterized by the development and growth of blood vessels from pre-existing vessels. Angiogenesis occurs during physiological processes such as embryonic development and corpus luteum formation, as well as in pathological circumstances such as tumorigenesis and chronic inflammation. The angiogenic process depends on the action of several molecules including angiogenic factors, ECM proteins, adhesion molecules and their receptors, and proteolytic enzymes (Ribatti and Crivellato, 2012). Several factors, including VEGF, FGF, TGF-β, PDGF, IL-8, and angiopoietin 1, are known to stimulate angiogenesis (Sawatsubashi et al. 2000; Taleja et al. 2004). The proximity of mast cells to blood vessels in tissues associated with angiogenesis has long suggested a relationship between mast cells and angiogenesis. Moreover, the role of mast cells in this process is most certainly related to the release of a large spectrum of angiogenic mediators, which include angiopoietin-1, FGF-2, VEGF, IL-8, TGF-β, TNF-α, histamine, heparin, tryptase and chymase, among others (Crivellato et al. 2004). These mast cell mediators can act at various stages of angiogenesis including degradation of the ECM, migration and proliferation of endothelial cells, formation and distribution of new vessels, synthesis of ECM and pericyte mobilization (D’Amore and Thompson 1987; Juczewska and Chyczewski 1997). It has been shown that during the initiation of angiogenesis, mast cell tryptase promotes ECM degradation through the activation of MMPs and plasminogen activator (Stack and Johnson 1994). In vitro and in vivo studies have shown that mMCP-4 has a role in the processing of pro-MMP-9 and pro-MMP-2 into their active forms (MMP-2 and MMP-9), both of which are released in parallel with mMCP4 and have a role in ECM remodeling and angiogenesis (Fang et al. 1996; Fang et al. 1997; Baram et al. 2001; Tchougouanova et al. 2005). Other mast cell granule contents, such as cathepsin G, elastase, and collagenase, also contribute to the degradation of ECM components (Stack and Johnson 1994). In addition, VEGF, FGF-2, and the combination of tryptase and heparin induces migration and proliferation of vascular endothelial cells (Azizkhan et al. 1980; Montesano et al. 1983; Bikfalvi et al. 1991; Blair et al. 1997; Jośko and Mazurek 2004). Histamine and heparin have also been shown to stimulate the proliferation of vascular endothelial cells and to induce the formation of new blood vessels in a rat mesenteric window assay (Sőrbo et al. 1994). Tryptase was able to promote vascular tube formation in vitro in a chorioallantoic membrane (CAM) assay (Ribatti et al. 1987; Blair et al. 1997). Additionally, in vitro studies have shown that the angiogenic factors VEGF, PDGF, and FGF-2 are chemotactic for mast cells (Gruber et al. 1995). Although most angiogenic mediators released are not exclusive to mast cells, the role of mast cell-specific proteases (chymases and tryptases) in angiogenesis has gained increased prominence. In particular, data indicate that mast cells are a significant source of angiogenic and tissue remodeling factors in the tumor environment. Mast cells constitute a major inflammatory cell population with a critical role in the regulation of inflammation and immune response which will be further discussed.

**Innate Immunity**

Similar to DCs, mast cells are among the first cells of the immune system to interact with antigens, toxins, and pathogens. In addition to their strategic distribution, mast cells express on their surface various receptors that are able to detect potentially harmful signals and enable the cells to respond rapidly and appropriately through the release of pre-stored and neo-synthesized mediators. Mast cells can recognize pathogens through different mechanisms including direct binding of pathogens or their components to PAMP receptors on the mast cell surface, binding of antibody or complement-coated bacteria to complement or immunoglobulin receptors, or recognition of endogenous peptides produced by infected or injured cells (Hofmann and Abraham 2009). The pattern of expression of these receptors varies considerably among different mast cell subtypes. TLRs (1-7 and 9), NLRs, RLRs, and receptors for complement are accountable for most mast cell innate responses (Marshall 2004; Metz et al. 2008; Fukuda et al. 2013; Graham et al. 2013). Activation of these receptors by pathogens leads to the release of inflammatory mediators, which contribute to the containment and clearance of the infection, and also support adaptive immune responses when necessary. The pattern of mediator release through
The role of mast cells in viral infections is less well characterized. Mast cells can be infected by several viruses including HIV, dengue virus, cytomegalovirus, adenoviruses, and Influenza A virus (IAV). Mast cell activation by viral products induces the production of a characteristic pattern of cytokines and chemokines that includes IL-1β, IL-6, CCL3, CCL4, CCL5, and CCL8 (Marshall et al. 2003; Dawicki and Marshall 2007; Burke et al. 2008). The ability of mast cells to promote recruitment of CD8+ T lymphocytes to the site of infection and to produce IFN-1 during viral challenge indicates that viral recognition by mast cells incites cellular responses directed towards viral clearance (Kulka et al. 2004; Orinska et al. 2005). An increased viral burden within the draining lymph nodes was observed in dengue virus-infected mast cell-deficient mice and this increase was shown to be due to deficient NK and NK T cell recruitment to the site of infection (St John et al. 2011). Another in vivo study showed a protective role for mast cells using a mouse model of skin viral infection, where vaccinia virus infection caused mast cell degranulation, which in turn led to antimicrobial peptide discharge and virus inactivation (Wang et al. 2012). Aoki et al. (2013) found that intradermal injection with herpes simplex virus 2 (HSV-2) into MC-deficient KitW/Wv mice led to increased clinical severity and mortality with elevated virus titers in HSV-infected skins. This outcome was reversed by intradermal reconstitution with BMMCs from wild-type, but not TNF−/− or IL-6−/−, mice, indicating a protective role for these cytokines in HSV-induced mortality. In addition to a role in viral clearance and immune surveillance, recent work from several groups has also suggested a detrimental role for mast cells in viral infections. For instance, HIV has been shown to infect human mast cell progenitors, which can mature and develop as long-lived viral reservoirs during latent infection (Sundstrom et al. 2007). Moreover, Graham et al. (2013) observed that mast cells contributed to the establishment of IAV-induced inflammatory response and lung damage.

In parasitic infections, the production and release of growth factors (IL-3, SCF, and IL-9) by mast cells were shown to be responsible for the commonly observed mast cell hyperplasia (Newlands et al. 1995; Faulkner et al. 1998; Lantz et al. 1998). Mast cell mediator release during parasitic infection promotes immune cell recruitment and regulation of gastrointestinal permeability. Moreover, the microenvironment generated in response to mast cell mediators produces favorable conditions for the expulsion of the parasite and containment of a chronic infection (Knight et al. 2000; Gurish et al. 2004; Abraham and St John 2010). It was recently reported that mast cell degranulation regulates tissue-derived cytokines IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) in the early stages of helminthic infection (Hepworth et al. 2012). These cytokines, produced mainly by epithelial and endothelial cells, have been reported to be critical for optimal Th2 responses and worm...
expulsion in helminth infections (Owyang et al. 2006; Allakherverdi et al. 2007b; Humphreys et al. 2008; Taylor et al. 2009). Hepworth et al. (2012) reported that innate IgE-independent regulation of tissue-derived cytokines was important for the appropriate development of an adaptive Th-2 response and the expansion of innate Th-2 cytokine-producing cells during helminthic infections.

Adaptive Immunity

Dendritic cells (DCs) are specialized antigen-presenting cells (APCs) and are indispensable for the induction of adaptive immune responses (Lambrecht et al. 2000; Vermaelen et al. 2001). Recent in vitro studies have shown that mast cells are also capable of processing and presenting antigens via MHC-I and MHC-II complexes (Malaviya et al. 1996; Poncet et al. 1999; Stelekati et al. 2009). Moreover, mast cells and their mediators also directly modulate activation and migration of DCs to lymph nodes (Reuter et al. 2010). Activation through TLR7 leads to the release of IL-1β and TNF, which promote migration of DCs from the skin to local lymph nodes and induce cytotoxic responses by T lymphocytes (Suto et al. 2006; Heib et al. 2007). Histamine, PGE_2, and PGD_2 modulate DCs to develop Th_2 responses (McIlroy et al. 2006; Theiner et al. 2006). During exocytosis, mast cells release exosomes, vesicles of heterogeneous size and shape derived from the lumen of multivesicular bodies and the plasma membrane (Harding et al. 1983; Raposo et al. 1997; Shefler et al. 2011). These mast cell-derived exosomes contain co-stimulatory molecules and antigens that promote functional and phenotypical maturation of DCs (Skokos et al. 2003). Moreover, mast cells can directly activate T lymphocytes through the release of TNF (Nakae et al. 2005; Nakae et al. 2006). In addition to promoting the initiation and development of adaptive immune responses, mast cells also act to limit the duration and magnitude of immune responses and are capable of suppressing immune responses through the release of anti-inflammatory cytokines such as IL-10 and TGF-β (Hart et al. 1998; Hart et al. 2002; Grimbaldeston et al. 2007; Rao and Brown 2008).

Immune Tolerance

The concept that mast cells function in the mediation of tolerance is relatively new. This view was based on the observation that mast cells were required to maintain immune tolerance (Lu et al. 2006). Further studies, most with skin mast cells, have demonstrated that, through their array of mediators, surface molecules, and co-stimulatory molecules, mast cells are able to modulate immune response both by contact-dependent and -independent mechanisms (de Vries and Noelle 2010). Mast cells are required for immune tolerance in allografts, and mast cell degranulation breaks this tolerance to established allografts (de Vries et al. 2009). Mast cell-secreted cytokines, in particular the neosynthesized cytokines IL-10 and TGF-β, are recognized for their immune-suppressive effects. Mast cell IL-10 secretion can reduce the duration and magnitude of immune responses. IL-10 and TGF-β downregulate the expression of FcεRI-limiting IgE-mediated degranulation (Gillespie et al. 2004; Gomez et al. 2005; Kennedy Norton et al. 2008). Mast cell-derived IL-10 promotes the containment and resolution of skin reactions caused by chronic UVB irradiation or contact dermatitis by limiting leukocyte infiltration, inflammation, epidermal hyperplasia, necrosis, and ulceration (Grimbaldeston et al. 2007). Moreover, interrupting the migration of mast cells to draining lymph nodes after UV damage abolishes the UV-induced immune suppression (Byrne et al. 2008). Along with other innate immune cells, mast cells are recruited by MIP-1α in the early stages of inflammation and binding of MIP-1α to the CCR1 receptor on the mast cell surface promotes the production of IL-6, TNF-α, and TGF-β (Fifadara et al. 2009). TGF-β, in addition to IL-2, is crucial for the development of DC-induced antigen-specific regulatory T cells (Treg) (Davidson et al. 2007; Luo et al. 2007). The Treg is CD4+, CD25+ and Fox3P+, develops in the thymus, and is crucial for self-tolerance. Treg cells suppress the proliferation of effector T cells through direct contact or release of anti-inflammatory cytokines such as TGF-β and IL-10, or other molecules like PGE2 (Zheng et al. 2004; Mahic et al. 2006). Interaction of Treg with mast cells is essential for Treg-dependent peripheral tolerance in skin allografts. Mast cells play an important role in peripheral tolerance in a manner that is dependent on CD4+, CD25+, Fox3P+ Treg in skin and heart transplants (Lu et al. 2006). Using a model of hapten-induced atopic dermatitis (AD), Hershko et al. (2011) showed that mast cell-derived IL-2 is necessary to support an adequate ratio of activated-to-regulatory T cells at the site of inflammation during the chronic phase of disease. Moreover, OX40L (CD252)-expressing mast cells interact directly with OX40-expressing Treg. This interaction inhibits mast cell degranulation and calcium mobilization without affecting cytokine secretion, thus reducing the amplitude of immediate hypersensitivity responses (Gri et al. 2008; Piconese et al. 2009; Frossi et al. 2011).

Mast cell proteases also contribute to immune tolerance in that they reduce antigenicity and leukocyte recruitment through cleavage of antigens, toxic peptides, cytokines, and chemotactic factors (Mellon et al. 2002; Pang et al. 2006; Rauter et al. 2006; Thakuradas et al. 2007; Rauter et al. 2008; Waern et al. 2009). Even though histamine is generally viewed as a proinflammatory mediator, its binding to histamine receptor 2 (H2R) mediates immune suppression as seen in mast cell-dependent, H2R-dependent immune suppression in response to UVB radiation (McGlade et al. 2007). In addition, there was a gradual loss of H2R expression on mast cells in lupus-like lesions (Furukawa et al. 2007). In addition, there was a gradual loss of H2R expression on mast cells in lupus-like lesions (Furukawa et al. 2007).
The Lipid mediator PGE2 also seems to have a role in immune suppression. Jet fuel immune suppression was impaired upon deletion of PGE2 from mast cells (Furukawa et al. 2009). Moreover, PGE2 induces IL-10 production in DCs and appears to inhibit DC maturation. These indirect effects can be blocked by cyclooxygenase (COX)-2 inhibitors and NSAIDs (non-steroidal anti-inflammatory drugs), which inhibit the synthesis of prostaglandins (Harizi and Gualde 2006; Sinha et al. 2007; Sá-Nunes et al. 2007; Lee et al. 2009).

**The Pathological Role of Mast Cells**

The same characteristics that enable mast cells to interact with the microenvironment and promptly release an array of mediators places this cell in a delicate position when the inadequate regulation of their functions can have serious consequences to the organism (Rao and Brown 2008).

**Allergy**

Allergies arise when components of the immune system, particularly mast cells, respond in an inappropriate manner to innocuous antigens. Mast cells are recognized as the main effector cell responsible for IgE-mediated allergic reactions. Sensitization is the primary immune response in which allergens are recognized, processed, and presented by APCs to naïve T lymphocytes that recognize the allergen as foreign and differentiate into Th2 lymphocytes. Th2 lymphocytes produce cytokines that then induce antigen-specific IgE production by B lymphocytes. Mast cells also have the capacity to process and present antigens through MHC class I and MHC class II complexes. Therefore, mast cells themselves have a role in sensitization. Furthermore, there is evidence that they coordinate and direct Th2 responses toward innocuous antigens (Eisenbarth et al. 2002; Nigo et al. 2006).

Initial studies on the relationship between mast cells and allergic reactions, including asthma, have focused on the acute phase of these reactions. FcεRI activation by a polyvalent allergen that is recognized by the receptor-bound IgE, leads to an immediate hypersensitivity reaction characterized by the instantaneous release of pre-formed and neoformed mast cell mediators. These mediators are responsible for allergic symptoms such as erythema, edema, increased vascular permeability, smooth muscle contraction, and augmented mucus secretion (Hofmann and Abraham 2009). The immediate release of histamine, PGD2, and LTC4 contributes to the symptoms of asthma, causing bronchoconstriction, mucus secretion, and respiratory mucosal edema. However, allergic reactions are complex and multiphasic. In addition to the immediate acute phase, there is also a late phase. In the later phases, pro-inflammatory cytokines released by mast cells are responsible for the recruitment of inflammatory cells such as eosinophils, basophils, and T cells to the site of inflammation and also contribute to the development of the chronic phase (Bradding 1999; Hofmann and Abraham 2009). The late phase is characterized by leukocyte infiltration at the site of inflammation and the initiation of an acquired immune response. This is followed by a chronic phase associated with persistent inflammation, tissue remodeling and fibrosis. These phases are observed in several allergic disorders including asthma, allergic rhinitis and atopic dermatitis, among others (Williams and Galli 2000; Grimbald eston et al. 2006; Brown et al. 2008).

**Crohn’s Disease**

Crohn’s disease is a chronic inflammatory intestinal disease, with the involvement of immune cells. However, there is no confirmation of an autoimmune etiology. This condition can affect any part of the gastrointestinal tract and causes diverse symptoms. Histologically, a perivascular distribution of lymphocytic infiltrates and the presence of occasional granulomas can be observed (Whitehead 1980). Stricture and fibrosis of gut, often resulting in partial or complete obstruction, is a common finding in Crohn’s disease. In Crohn’s disease, the mast cells are redistributed and found in the muscle layers of the stricture, which has led to the suggestion that mast cells and their mediators may play a role in stricture formation (Dvorak et al. 1980a; Dvorak et al. 1980b; Gelbmann et al. 1999). There is also evidence of increased expression of IL-16 in Crohn’s disease. This cytokine can be produced and released by mast cells, indicating a possible association between mast cell activation and CD4+ T lymphocyte recruitment during the inflammatory response. Moreover, mast cells are located near blood vessels and mast cell-released IL-16 can recruit circulating lymphocytes from the blood stream (Middel et al. 2001).

**Autoimmune Diseases**

When the immune system fails to recognize self from non-self molecules, self-reactive lymphocytes can be activated by innate immune cells and mount an autoimmune response. It is widely accepted that mast cells can promote increased inflammation in several disease states. In accord with this view, mast cells are able to stimulate the priming of autoreactive T cells and recruit immune cells to the site of inflammation. The inflammatory environment favored by mast cells can induce T cell activation. In this context, mast cells can act in concert with T cells to cause tissue damage (Christy and Brown 2007).

There are several examples of mast cell association with autoimmune diseases including: Type I diabetes, Guillain-Barré syndrome, bullous pemphigoid, Sjogren syndrome, chronic idiopathic urticaria and experimental vasculitis (Wintroub et al. 1978; Yamamoto et al. 1995; Dines and Powell 1997; Geoffrey et al. 2006; Ishii et al. 2009; Saini et al. 2009). Much of the interest on the role of mast cells in
the initiation and propagation of autoimmune diseases comes from studies on multiple sclerosis (MS) and its experimental model, allergic encephalitis (EAE) (Steinman 2001; Nigrovic and Lee 2007).

MS is a chronic inflammatory disease of the nervous system of unknown etiology, characterized by a deterioration of the blood-brain barrier, with consequent mononuclear cell infiltration into the white matter and eventual demyelination of axons. EAE depends on inflammatory CD4^+ Th17 cells, B cells, and antibodies produced by these cells (Weaver et al. 2006). Many studies suggest a positive correlation of mast cell numbers and distribution with the development of MS or EAE (Orr 1988; Brenner et al. 1994; Ibrahim et al. 1996; Dines and Powell 1997; Brown et al. 2002). The observation of increased degranulation and the presence of tryptase in the cerebrospinal fluid provides evidence for an increase in mast cell activation during the course of the disease (Brenner et al. 1994; Rozniecki et al. 1995). Drugs known to stabilize mast cells, such as sodium cromoglicate, seem to relieve the severity of EAEs (Seeldrayers et al. 1989). Mast cell function in this context appears to depend on the surface binding of IgGs, because disease progression relies on the expression of FcγR by mast cells (Brown et al. 2002). Kit<sup>W<sup>W^v</sup></sup> and Kit<sup>W<sup>ash</sup></sup> were reported to be more resistant than wild type mice to the myelin oligodendrocyte glycoprotein (MOG) peptide-induced EAE (Secor et al. 2000).

Another autoimmune disease involving mast cells is rheumatoid arthritis, a chronic inflammatory disease of the joints. The cause of this disease may be associated with the enzyme glucose-6-phosphate isomerase (GPI) (Matsumoto et al. 1999; Zhang et al. 2011). A widely used model for rheumatoid arthritis is the K/BxN mouse. These mice express both the T cell receptor transgene KRN and the MHCII molecule A(γ7). They produce auto-antibodies recognizing GPI and also develop a severe inflammatory arthritis. Serum from these mice causes a similar arthritis in a wide range of mouse strains. The antibodies form aggregates with GPI leading to the deposition of immune complexes on the surface of the articular cavity. These complexes initiate a signaling cascade that involves neutrophils as well as mast cells. The complement pathway, FcRs, and cytokines such as IL-1 and TNF are all involved (Ravetch and Bolland 2001; Ji et al. 2002b; Ji et al. 2002a; Hueber et al. 2010). Notably, FcγRIII activation by immune complexes has been implicated as an important event for the development of RA in this model (Corr and Crain 2002; Ji et al. 2002b; Nigrovic et al. 2007). Kit<sup>W<sup>W^v</sup></sup> mice deficient in mast cells are resistant to autoimmune inflammatory arthritis induced by injection of sera from K/BxN mice and the mast cell reconstitution of these animals restores their sensitivity. However, mast cell-reconstituted Kit<sup>W<sup>ash</sup></sup> mice are still susceptible to arthritis induced by sera from K/BxN mice (Lee et al. 2002a; Zhou et al. 2007).

Mast cells accumulate in the synovial tissues and fluids of patients with rheumatoid arthritis and produce inflammatory mediators. In fact, mast cell degranulation in the articular cavity is one of the first events observed after antibody administration (Lee et al. 2002a). Results using this model also show that activation of mast cells through the IgG immune complex receptor FcγRIII can precipitate the initiation of inflammation within the joint through the production and release of IL-1 (Nigrovic et al. 2007). In addition, mast cell-derived TNF-α, can induce fibroblasts to produce SCF, which increases the recruitment of mast cells and creates an amplification loop (Woolley and Tetlow 2000; Benoist and Mathis 2002).

Despite mounting evidence of the involvement of mast cells in these autoimmune disease models, Feyerabend et al. (2011), using the mouse strain Cpa<sup>3<sup>Cre<sup>+</sup></sup></sup>, which is deficient exclusively in mast cells, found no evidence for an active role of mast cells both in the K/BxN serum transfer model of RA and the EAE model of MS. In fact, the precise contribution of mast cells to the pathophysiology of autoimmune diseases remains a matter of great debate (reviewed in Brown and Hatfield 2012).

**Mastocytosis**

Mastocytosis is disorders characterized by the clonal accumulation of mast cells and their products in organs such as skin, gastrointestinal tract, bone marrow, liver, spleen, and lymph nodes (Horny et al. 2008). They are usually caused by activating mutations of the c-Kit receptor (Metcalfe 2008; Deho' and Monticelli 2010). Mastocytosis presents many variants, which display a range of symptoms and prognoses. The two main variants are cutaneous mastocytosis (CM) and systemic mastocytosis (SM), which are based on disease distribution and clinical manifestation. Clinical manifestations of this pathology include pruritus, flushing, nausea, vomiting, diarrhea, and vascular instability (Metcalfe 2008). CM is most common in children and presents in three forms: (i) urticaria pigmentosa or maculopapular mastocytosis; (ii) diffuse cutaneous mastocytosis, and (iii) mastocytomas. SM is characterized by the involvement of at least one extracutaneous organ, even in the absence of skin lesions. There are many variants of SM, including indolent systemic mastocytosis, bone marrow mastocytosis, mastocytic leukemia, and mastocytic sarcoma (WHO 2008). A diagnosis of mastocytosis is based on histological confirmation of mast cell accumulation, whereas classification of systemic mastocytosis is contingent on the correlation between clinical and laboratory evaluations (Valent et al. 2001). Mast cell metachromatic granules can be observed with Giemsa and toluidine blue staining. However, tissue processing can diminish mast cell granule staining, which is typically less prominent in abnormal neoplastic mast cells. Due to these difficulties immunophenotypic studies become a more suitable choice.
in the diagnosis of mastocytosis (Li 2001). Neoplastic mast cells express CD33, CD43, CD68, CD117 and tryptase, of which tryptase is the only marker exclusive to mast cells (Valent et al. 1992; Yang et al. 2000; Miettinen and Lasota 2005; Chiu and Orati 2012). Moreover, neoplastic mast cells usually express CD2 and/or CD25, which are not expressed in normal mast cells (Jordan et al. 2001; Escribano et al. 2002; Sotlar et al. 2004; Krokowski et al. 2005).

The prognosis depends on the type of mastocytosis. Although childhood and adult-onset mastocytosis are both associated with activating mutations, the course of the disease is very different. Children often present a skin-limited disease that regresses with age, whereas adults generally present with persistent multi-organ involvement that is often accompanied by a second non-mast cell hematologic neoplasm (Pardanani 2012).

**Cardiovascular Disease**

Increasing evidence implicates cardiac mast cells in coronary disease. Cardiac mast cells participate in the development of atherosclerosis, coronary inflammation, and cardiac ischemia (Patella et al. 1995). These types of mast cells are more evident in the adventitial tunic of coronary arteries during spasm (Forman et al. 1985) and accumulate in the angular region of atherosclerotic plaques (Kaartinen et al. 1994; Constantinides 1995). In the heart, chymase is the main source of the converting enzyme that produces the coronary constrictor angiotensin II (Jenne and Tschopp 1991). Both chymase and tryptase released by mast cells induce proteolytic changes in high-density lipoprotein (HDL) particles, which interfere with cholesterol efflux by macrophages leading to the formation of foam cells that constitute the atheroma (Lindstedt et al. 1996; Lee et al. 2002b; Lee et al. 2003).

**Cancer**

The tumor microenvironment is comprised of fibroblasts, myofibroblasts, ECM, existing and newly formed blood vessels, and inflammatory cells. The relationship between mast cells, inflammation, and cancer is contradictory and consists of both promotion of and protection against tumor progression. Mast cell accumulation is typically observed around rodent and human tumors. This accumulation is associated with a poor prognosis in various cancers and suggests an involvement of mast cells in tumor progression (Takanami et al. 2000; Conti et al. 2007). However, the opposite has been observed in some breast cancers (Dabiri et al. 2004). Mast cells are recruited by tumor-derived factors. One of these factors, SCF, induces mast cell infiltration and activation, with the consequential release of inflammatory mediators that participate in tissue remodeling and immune suppression (Huang et al. 2008). The role of mast cells in cancer promotion includes immunosuppression, the release of pro-angiogenic and mitogenic factors, and degradation of the ECM (Ch’ng et al. 2006). Tumor histamine content correlates positively with mast cell numbers in breast carcinomas (Bowrey et al. 2000). Histamine can simultaneously stimulate tumor proliferation through its interaction with histamine H1 receptors and suppress the immune system through H2 receptors, thus contributing to carcinogenesis (Conti et al. 2007). Mast cell modulation of the immune response through the release of histamine, IL-10, and TNF-α, contributes to tumor growth. In colorectal carcinoma, mast cells may counteract the anti-inflammatory function of regulatory T cells, and mast cell-mediated immunosuppression may contribute to the development of basal cell carcinoma (Hart et al. 2001; Blatner et al. 2010). It is believed that mast cells participate in tumorigenesis through the release of pro-angiogenic factors such as heparanase, angiopoietin-1, TNF, FGF-2, VEGF, and IL-18 in addition to mast cell-specific proteases that assist in ECM degradation and subsequent tumor invasion (Ribatti et al. 2001; Maltby et al. 2009). Stimulation of angiogenesis is probably the most important function of mast cells in the promotion of tumor growth (Dyduch et al. 2012). VEGF, FGF-2, TGF-β, TNF-α, and IL-18 are all potent pro-angiogenic factors. A role for mast cell-specific proteases has also been proposed (Muramatsu et al. 2000b; Muramatsu et al. 2000a; Tóth-Jakatics et al. 2000; Norrby, 2002; Feoktistov et al. 2003; Yoshii et al. 2005). It has recently been observed that mast cells, through the action of their specific proteases, are involved in the initial phases of tumor growth and also in modulating vascular growth in the later stages of tumor progression (de Souza et al. 2012). Mast cells also secrete proteases such as MMP-2 and MMP-9, which digest ECM and, together with heparin, stimulate heparin-binding pro-angiogenic factors in the tumor microenvironment, thus influencing tumor progression and metastasis (Coussens et al. 1999; Baram et al. 2001; Norrby 2002). In mast cell-deficient mice, tumor induction was accompanied by reduced angiogenesis and metastatic capacity (Ribatti et al. 2001).

The anti-neoplastic effects of mast cells include inhibition of cell growth, an augmented inflammatory anti-tumor reaction, induction of apoptosis, and decreased cell mobility (Dyduch et al. 2012). TNF-α, IL-1, and IL-6 were reported to suppress melanoma growth, and prostacyclin, which is produced by endothelial cells in response to histamine, is a potent anti-metastatic factor (Dyduch et al. 2012). IL-6 production and release in response to TLR-2 activation was shown to inhibit tumor growth both in vivo and in vitro (Oldford et al. 2010). Furthermore, eosinophil recruitment and survival, promoted by mast cell tryptase and IL-5, respectively, leads to tumor regression (Maltby et al. 2009).

The clinical relevance of the mast cell/tumor relationship remains to be discovered. Nonetheless, mast cells have been shown to be involved in tumor progression and
neangiogenesis in several cancer types (Takanami et al. 2000; Benitez-Bribiesca et al. 2001; Grimaldoston et al. 2004; Ribatti et al. 2005; Yoshi et al. 2005; Ch’ng et al. 2006; Diazon et al. 2007; Nonomura et al. 2007; Fleischmann et al. 2009; Carlini et al. 2010; Johansson et al. 2010; Ribatti et al. 2010).

In conclusion, mast cells are ancient cells whose ancestor is a urochordate mast cell-like cell 550-million years old. Although mammalian mast cells were first described more than a century ago, their detailed functions still remain to be elucidated. Today, mast cells are considered to be multifunctional immune cells implicated in several physiological and disease states. As a consequence of their widespread location and the mediators or the pathogens they interact with, mast cells exhibit a high degree of heterogeneity and plasticity. It is increasingly evident that mast cell maturation, phenotype, and function are dictated by the local microenvironment which has a significant influence on ability of mast cells to recognize and respond to stimuli. The widespread tissue distribution of mast cells and their versatility allow them to respond to harmful situations as a first-response and respond to environmental changes through the interactions with other cells implicated in physiological and immunological responses. Their ubiquitous distribution places mast cells in a privileged position to act not only as guardians of the immune system, but to also participate in many biological processes and in the maintenance of homeostasis. Mast cells have both immunomodulatory as well as physiological functions. It is currently acknowledged that mast cells modulate innate and adaptive immune responses, both directly and indirectly, through communication with other immune cells. Moreover, mast cells are able to modulate immune responses through their array of mediators, surface molecules, and co-stimulatory molecules.

During the lifetime of a mast cell, numerous factors can alter its phenotype and a combination of these changes can determine mast cell homeostatic or pathophysiological responses. Those features that provide mast cells with the ability to interact with the microenvironment are the same ones that, when inadequately regulated, can have serious consequences to the organism. Mast cell contributions for many disease states are thus the focus of continuous assessment.

Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Financial support was obtained from FAEPF, FAPESP (Fellowship 2012/06373-0 to EZMDS) and CNPq (Fellowship 161304/2011-7 to EZMDS).

References
Abe M, Kurosawa M, Ishikawa O, Miyachi Y (2000). Effect of mast cell-derived mediators and mast cell-related neutral proteases on human dermal fibroblast proliferation and type I collagen production. J Allergy Clin Immunol 106:S78-S84.
Abonia JP, Austen KF, Rollins BJ, Joshi SK, Flavell RA, Kuziel WA, Koni PA, Gurish MF (2005). Constitutive homing of mast cell progenitors to the intestine depends on autologous expression of the chemokine receptor CXCR2. Blood 105:4308-4313.
Abonia JP, Hallgren J, Jones T, Shi T, Xu Y, Koni P, Flavell RA, Boyce JA, Austen KF, and Gurish MF (2006). Alpha-4 integrins and VCAM-1, but not MadCAM-1, are essential for recruitment of mast cell progenitors to the inflamed lung. Blood 108:1588-1594.
Abonia JP, Blanchard C, Butz BB, Rainey HF, Collins MH, Stringer K, Putnam PE, Rothenberg ME (2010). Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol 126:140-149.
Abraham SN, and St John AL (2010). Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10:440-452.
Abramson J, Xu R, Pecht I (2002). An unusual inhibitory receptor—the mast cell function-associated antigen (MAFA). Mol Immunol 38:1307-1313.
Abrink M, Grujic M, Pejler G (2004). Serglycin is essential for maturation of mast cell secretory granule. J Biol Chem 279:40897-40905.
Aceves SS, Chen D, Newbury RO, Dohil R, Bastian JF, Broide DH (2010). Mast cells infiltrate the esophageal smooth muscle in patients with eosinophilic esophagitis, express TGF-β1, and increase esophageal smooth muscle contraction. J Allergy Clin Immunol 126:1198-1204.e1194.
Ackermann L, Harvima IT, Pelkonen J, Ritamäki-Salo V, Naukkarinen A, Harvima RJ, Horsmanheimo M (1999). Mast cells in psoriatic skin are strongly positive for interferon-γ. Br J Dermatol 140:624-633.
Akahoshi M, Song CH, Piliponsky AM, Metz M, Guzzetta A, Abrink M, Schlenner SM, Feyerabend TB, Rodewald HR, Pejler G, Tsai M, Galli SJ (2011). Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice. J Clin Invest 121:4180-4191.
Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C, Kuehn N, Gray A, Giddings J, Peskett E, Fox R, Bruce I, Walker C, Sawyer C, Okkenhaug K, Finan P, Vanhaesebroeck B (2004). Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. Nature 431:1007-1011.
Allakhverdi Z, Smith DE, Comeau MR, Delespese G (2007a). Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 178:2051-2054.
Allakhverdi Z, Comeau MR, Jessup HK, Yoon BR, Brewer A, Chartier S, Paquette N, Ziegler SF, Sarfati M, Delespese G (2007b). Thymic stromal lymphopoietin is released by human...
epithelial cells in response to microbes, trauma, or inflammation and potentially activates mast cells. J Exp Med 204:253-258.

Alvarez-Errico D, Sayós J, López-Botet M (2007). The IREM-1 (CD300f) inhibitory receptor associates with the p85alpha subunit of phosphoinositide 3-kinase. J Immunol 178:808-816.

Aoki R, Kawamura T, Goshima F, Ogawa Y, Nakae S, Nakao A, Morishiki K, Nishiyama Y, Shimada S (2013). Mast cells play a key role in host defense against herpes simplex virus infection through TNF-α and IL-6 production. J Invest Dermatol 133:2170-2179.

Arimbou Y, Iwasaki H, Akashi K (2009). Origin of basophils and mast cells. Allergol Int 58:21-28.

Arimbou Y, Iwasaki H, Gurish MF, Mizuno S, Shigematsu H, Ozawa H, Tenen DG, Austen KF, Akashi K (2005). Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc Natl Acad Sci U S A 102:18105-18110.

Artis D, Humphreys NE, Potten CS, Wagner N, Müller W, McDermott JR, Grencis RK, Else KJ (2000). Beta7 integrin-deficient mice: delayed leukocyte recruitment and attenuated protective immunity in the small intestine during enteric helminth infection. Eur J Immunol 30:1656-1664.

Azizkhan RG, Azizkhan JC, Zetter BR, Folkman J (1980). Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J Exp Med 152:931-944.

Balzar S, Chu HW, Strand M, Wenzel S (2005). Relationship of small airway chymase-positive mast cells and lung function in severe asthma. Am J Respir Crit Care Med 171:431-439.

Baram D, Vaday GG, Salamon P, Drucker I, Hershkovitz R, Mekori YA (2001). Human mast cell release metalloprotease-9 on contact with activated T cells: Juxtacrine regulation by TNF-alpha. J Immunol 167:4008-4016.

Bashkin P, Razin E, Eldor A, Vlodavsky I (1990). Degranulating mast cells secrete an endoglycosidase that degrades heparan sulfate in subendothelial extracellular matrix. Blood 75:2204-2212.

Basu S, Fenton MJ (2004). Toll-like receptors: function and roles in lung disease. Am J Physiol Lung Cell Mol Physiol 286, L887-892.

Beil WJ, Login GR, Galli SJ, Dvorak AM (1994). Ultrastructural immunogold localization of tumor necrosis factor-alpha to the cytoplasmic granules of rat peritoneal mast cells with rapid microwave fixation. J Allergy Clin Immunol 94:531-536.

Benditt EP, Wong RL, Arase M, Roep E (1955). 5-Hydroxytryptamine in mast cells. Proc Soc Exp Biol Med 90:303-304.

Benhamou M, Siraganian R (1992). Protein-tyrosine phosphorylation: an essential component of Fc epsilon RI signaling. J Immunol Today 13:195-197.

Benoist C, Mathis D (2002). Mast cells in autoimmune disease. Nature 420:875-878.

Benítez-Bribiesca L, Wong A, Utrera D, Castellanos E (2001). The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem 49:1061-1062.

Bergera F, Humbert L, Bereziat G, Thirion S (2003). Comcomitant recruitment of ERK1/2 and p38 MAPK signaling pathway is required for activation of cytoplasmic phospholipase A2 via ATP in articular chondrocytes. J Biol Chem 278:13680-13687.

Berlanga O, Emanbokus N, Frampton J (2005). GPIIb (CD41) integrin is expressed on mast cells and influences their adhesion properties. Exp Hematol 33:403-412.

Biedermann T, Kneiling M, Mailhammer R, Maier K, Sander CA, Kollias G, Kunkel SL, Hültner L, Röcken M (2000). Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 192:1441-1452.

Bilikfali A, Suaezau C, Moukadiri H, Maclouf J, Busso N, Bryckaert M, Plouet J, Tobelem G (1991). Interaction of vascular/endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects. J Cell Physiol 149:50-59.

Bischoff DC, Dahinden CA (1992). c-kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med 175:237-244.

Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, Gruber BL (1997). Human mast cells stimulate vascular tube formation. J Immunol 99:2691-2700.

Blatter NR, Bonertz A, Beckhove P, Cheon EC, Krantz SB, Strouch M, Weitz J, Koch M, Halverson AL, Bentrem DJ, Khazaie K (2010). In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci U S A 107:6430-6435.

Bochner BS (2009). Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin Exp Allergy 39:317-324.

Boesiger J, Tsai M, Mauer M, Yamaguchi M, Brown LF, Claffey KP, Dvorak HF, Galli SJ (1998). Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression. J Exp Med 188:1135-1145.

Boie Y, Sawyer N, Slipetz DM, Metters KM, Abramovitz M (1995). Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem 270:18910-18916.

Bowrey PF, King J, Magarey C, Schwartz P, Marr P, Bolton E, Morris DL (2000). Histamine, mast cells and tumour cell proliferation in breast cancer: does preoperative cinmetidine administration have an effect? Br J Cancer 82:167-170.

Boyce JA (2005). Eicosanoids mediate mast cells: receptors, regulation of synthesis, and pathobiologic implications. Chem Immunol Allergy 87:59-79.

Boyce JA (2007). Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. Immunol Rev 217:168-185.

Bradding P (1999). Allergen immunotherapy and mast cells. Clin Exp Allergy 29, 1445-1448.

Brenner T, Soiffer D, Shalit M, Levi-Schaffer F (1994). Mast cells in experimental allergic encephalomyelitis: characterization, distribution in the CNS and in vitro activation by myelin basic protein and neuropeptides. J Neurol Sci 122:210-213.

Brown J, Wilson T, Metcalfe D (2008). The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin and Exp Allergy 38:4-18.
Brown MA, Tanzola MB, Robbie-Ryan M (2002). Mechanisms underlying mast cell influence on EAE disease course. Mol Immunol 38:1373-1378.

Brown MA, Hatfield JK (2012). Mast Cells are Important Modifiers of Autoimmune Disease: With so Much Evidence, Why is There Still Controversy? Front Immunol 3:147.

Buckland J (2010). New role for mast cells as IL-17-expressing effector cells in established NA. Nat Rev Rheumatol 6:243.

Bulfone-Paus S, Paus R (2008). Osteopontin as a new player in mast cell biology. Eur J Immunol 38:338-341.

Burd PR, Rogers HW, Gordon JR, Martin CA, Jayaraman S, Wilson SD, Dvorak AM, Galli SJ, Dorf ME (1989). Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines. J Exp Med 170:245-257.

Burke SM, Issekutz TB, Mohan K, Lee PW, Shmulevitz M, Marshall JS (2008). Human mast cell activation with virus-associated stimuli leads to the selective chemotaxis of natural killer cells by a CXCL8-dependent mechanism. Blood 111:5467-5476.

Burton OT, Darling AR, Zhou JS, Noval-Rivas M, Jones TG, Gurih MF, Chatila TA, Oettgen HC (2013). Direct effects of IL-4 on mast cells drive their intestinal expansion and increase susceptibility to anaphylaxis in a murine model of food allergy. Mucosal Immunol 6:740-750.

Butterfield JH, Weiler D, Peterson EA, Gleich GJ, Leiferman KM (1990). Sequestration of eosinophil major basic protein in human mast cells. Lab Invest 62:77-86.

Byrne SN, Limón-Flores AY, Ullrich SE (2008). Mast cell migration from the skin to the draining lymph nodes upon ultraviolet irradiation represents a key step in the induction of immune suppression. J Immunol 180:4648-4655.

Campagna S, Saint N, Molle G, Aumelas A (2007). Structure and mechanism of action of the antimicrobial peptide piscidin. Biochemistry 46:1771-1778.

Carlini MJ, Dalurzo MC, Lastiri JM, Smith DE, Vasallo BC, Puricelli LI, Lauria de Cidre LS (2010). Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance. Hum Pathol 41:697-705.

Carlos D, Machado ER, De Paula L, Sá-Nunes A, Sorgi CA, Jamur CL (2010). The role of the CCL2/CCR2 axis in mouse mast cell migration in vitro and in vivo. J Immunol 184:6114-6123.

Combs J (1966). Maturation of rat mast cells. An electron microscope study. J Cell Biol 31:563-575.

Constantinides P (1995). Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 92:1083.

Conti P, Castellani ML, Kemparaj D, Salini V, Vecchiet J, Tette S, Mastrangelo F, Perrella A, De Lutiis MA, Tagen M, Theoharides TC (2007). Role of mast cells in tumor growth. Eur J Immunol 37:2673-2679.

Cherwinski HM, Murphy CA, Joyce BL, Bigler ME, Song YS, Zurawski SM, Moshefi MM, Gorman DM, Miller KL, Zhang S, Sedgwick JD, Phillips JJH (2005). The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J Immunol 174:1348-1356.

Chiapetta N, Gruber B (2006). The role of mast cells in osteoporosis. Semin Arthritis Rheum 36:32-36.

Chiu A, Orazi A (2012). Mastocytosis and related disorders. Semin Diagn Pathol 29:19-30.

Cho SH, Woo CH, Yoon SB, Kim JH (2004). Protein kinase C delta functions downstream of Ca2+ mobilization in Fc epsilonRI signaling to degranulation in mast cells. J Allergy Clin Immunol 114:1085-1092.

Choi OH, Kim JH, Neten JP (1996). Calcium mobilization via sphingosine kinase in signalling by the Fc epsilon RI antigen receptor. Nature 380:634-636.

Christy AL, Brown MA (2007). The multitasking mast cell: positive and negative roles in the progression of autoimmunity. J Immunol 179:2673-2679.

Clark J, Lin L, Kriz R, Ramesha C, Sultzman L, Lin A, Milona N, Knopf J (1991). A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+-dependent translocation domain with homology to PKC and GAP. Cell 65:1043-1051.

Coelho AM, Vergnolle N, Guiard B, Fioramonti J, Bueno L (2002). Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats. Gastroenterology 122:1035-1047.

Collington SJ, Williams TJ, Weller CL (2011). Mechanisms underlying the localisation of mast cells in tissues. Trends Immunol 32:478-485.

Collington SJ, Hallgren J, Pease JE, Jones TG, Rollins BJ, Westwick J, Austen KF, Williams TJ, Gurish MF, Weller CL (2010). The role of the CCL2/CCR2 axis in mouse mast cell migration in vitro and in vivo. J Immunol 184:6114-6123.

Combs J (1966). Maturation of rat mast cells. An electron microscope study. J Cell Biol 31:563-575.
induces parallel increases in the frequency of P cell precursors and mast cells. J Immunol 131:923-928.

Crivellato E, Beltrami CA, Mallard F, Ribatti D (2004). The mast cell: an active participant or an innocent bystander? Histol Histopathol 19:259-270.

Cumano A, Ferraz JC, Klain M, Di Santo JP, Godin I (2001). Intraembryonic, but not yolk sac hematopoietic precursors, isolated before circulation, provide long-term multilineage reconstitution. Immunity 15:477-485.

D’Amore PA, Thompson RW (1987). Mechanisms of angiogenesis. Annu Rev Physiol 49:453-464.

Dabiri S, Huntsman D, Makretsov N, Cheang M, Gilks B, Bajdik C, Badjk C, Gelmon K, Chia S, Hayes M (2004). The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol 17:690-695.

Dahl C, Hoffmann HJ, Saito H, Schiotz PO (2004). Human mast cells express receptors for IL-3, IL-5 and GM-CSF; a partial map of receptors on human mast cells cultured in vitro. Allergy 59:1087-1096.

Dawicki W, Marshall JS (2007). New and emerging roles for mast cells in host defence. Curr Opin Immunol 19:31-38.

Deho' L, Monticelli S (2010). Human mast cells and mastocytosis: harnessing microRNA expression as a new approach to therapy? Arch Immunol Ther Exp (Warsz) 58:279-286.

Di Nardo A, Vitiello A, Gallo RL (2003). Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 170:2274-2278.

Di Nardo A, Yamasaki K, Dorschner RA, Lai Y, Gallo RL (2008). Mast cell cathelicidin antimicrobial peptide prevents invasive group A Streptococcus infection of the skin. J Immunol 180:7565-7573.

Diaconu NC, Kaminska R, Naukkarien Ar, Harvinma RJ, Harvinma IT (2007). The increase in tryptase- and chymase-positive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in basal cell carcinoma. J Eur Acad Dermatol Venereol 21:908-915.

DiAugustine RP, Lazarus LH, Jahneke G, Khan MN, Erisman MD, Linnoila RI (1980). Corticotropin/beta-endorphin immunoreactivity in rat mast cells. Peptide or protease? Life Sci 27:2663-2668.

Dietrich N, Rohde M, Geffers R, Kröger A, Hauser H, Weiss S, Gekara KO (2010). Mast cells elicit proinflammatory but not type I interferon responses upon activation of TLRs by bacteria. Proc Natl Acad Sci U S A 107:8748-8753.

Dines KC, Powell HC (1997). Mast cell interactions with the nervous system: relationship to mechanisms of disease. J Neuropathol Exp Neurol 56:627-640.

Dixon RA, Diehl RE, Opas E, Rand E, Vickers PJ, Evans JF, Gillard JW, Miller DK (1990). Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343:282-284.

Dougherty RH, Sidhu SS, Raman K, Solon M, Solberg OD, Caughey GH, Woodruff PG, Fahy JV (2010). Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma. J Allergy Clin Immunol 125:1046-1053.e1048.

Dragoneetti A, Baldassarre M, Castino R, Démoz M, Luini A, Bucciore R, Isidoro C (2000). Definitive hematopoietic stem cells first develop within the major arterial regions of the mouse embryo. EMBO J 19:2465-2474.

de Cásia Campos MR, Toso TD, de Souza DA, Vieira GV, da Silva EZ, Oliver C, Janur MC (2014). Differential effects of chemotactants on mast cell recruitment in vivo. Cell Immunol 289:86-90.

di Castro R, Zhan J, Janur M, Oliver C, Siraganian R (2010). Tyrosines in the carboxyl terminus regulate Syk kinase activity and function. J Biol Chem 285:26674-26684.

de Filippo K, Dudeck A, Hasenberg M, Nye E, van Rooijen N, Hartmann K, Gunzer M, Roers A, Hogg N (2013). Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood 121:4930-4937.

de Souza DA Jr, Toso TD, Campos MRC, Lara VS, Oliver C, Janur MC (2012). Expression of Mast Cell Proteases Correlates with Mast Cell Maturation and Angiogenesis during Tumor Progression. PLoS ONE 7, e40790.

de Vries VC, Noelle RJ (2010). Mast cell mediators in tolerance. Curr Opin Immunol 22:643-648.
II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils, and the microvasculature. Hum Pathol 11:606-619.

Dvorak AM, Osage JE, Monahan RA, Dickerson GR (1980b). Crohn’s disease: transmission electron microscopic studies. III. Target tissues. Proliferation of and injury to smooth muscle and the autonomic nervous system. Hum Pathol 11:620-634.

Dyduch G, Kaczmarczyk K, Oiko K (2012). Mast cells and cancer: enemies or allies? Pol J Pathol 63:1-7.

Dzierzak E, Speck NA (2008). Of lineage and legacy: the development of mammalian hematopoietic stem cells. Nat Immunol 9:129-136.

Dery O, Corvera CU, Steinhoff M, Bunnett NW (1998). Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 274, C1429-1452.

Edvinsson L, Cervós-Navarro J, Larsson LI, Owman C, Rönnberg AL (1977). Distribution of mast cells containing histamine, dopamine, or 5-hydroxytryptamine in the mammalian brain. Neurology 27:878-883.

Ehrenreich H, Burd PR, Rottem M, Hültner L, Hylton JB, Garfield M, Coligan JE, Metcalfe DD, Fauci AS (1992). Endothelins belong to the assortment of mast cell-derived and mast cell-bound cytokines. New Biol 4:147-156.

Ehrlich P (1878). Beitra¨ge zur Theorie und Praxis der histologischen Fa¨rbung. (Leipzig University.).

Eisenbarth SC, Piggott DA, Hulett JW, Visintin I, Herrick CA, Eisenbarth SC, Piggott DA, Hulett JW, Visintin I, Herrick CA, Bottomly K (2002). Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 196:1645-1651.

Endo S, Hochman DJ, Midoro-Horiuti T, Goldblum RM, Brooks EG (2011). Mountain cedar pollen induces IgE-independent mast cell degranulation, IL-4 production, and intracellular reactive oxygen species generation. Cell Immunol 271:488-495.

Enerbäck L (1966a). Mast cells in rat gastrointestinal mucosa. 2. Dye-binding and metachromatic properties. Acta Pathol Microbiol Scand 66:303-312.

Enerbäck L (1966b). Mast cells in rat gastrointestinal mucosa. I. Effects of fixation. Acta Pathol Microbiol Scand 66:289-302.

Enerbäck L, Pipkorn U, Granerus G (1986). Intraepithelial migration of nasal mucosal mast cells in hay fever. Int Arch Allergy Immunol 80:44-51.

Enerbäck L, Kolset SO, Kusche M, Hjerpe A, Lindahl U (1985). Glycosaminoglycans in rat mucosal mast cells. Biochem J 227:661-668.

Escobedo L, Díaz-Agustín B, Núñez R, Prados A, Rodriguez R, Orfao A (2002). Abnormal expression of CD antigens in mastocytosis. Int Arch Allergy Immunol 127:127-132.

Evans JF, Dupuis P, Ford-Hutchinson AW (1985). Purification and characterisation of leukotriene A4 hydrolase from rat neutrophils. Biochim Biophys Acta 840:43-50.

Falanga YT, Chaimowitz NS, Charles N, Finkelman FD, Pullen NA, Barbour S, Dhalaria K, Faber T, Kolawole M, Huang B, Odom S, Rivera J, Carlyon J, Conrad DH, Spiegel S, Öskeritzian CA, Ryan JJ (2012). Lyn but not Fyn kinase controls IgG-mediated systemic anaphylaxis. J Immunol 188:4360-4368.
García-Faroldi G, Rodríguez CE, Urdiales JL, Pérez-Pomares JM, García-Faroldi G, Melo FR, Rönnberg E, Grujic M, Pejler G, Galli SJ, Tsai M, Wershil BK (1993b). The c-receptor. Stem cell factor and mast cells. J Clin Invest 91:148-152.

Galli S, Tsai M, Wershil BK (1993b). The c-receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol 142:965-974.

Gelbmann CM, Mestermann S, Gross V, Köllinger M, Schölmerich J, Falk W (1999). Strictures in Crohn’s disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut 45:210-217.

Geoffrey R, Jia S, Kwaitek AE, Woodliff J, Ghosh S, Lernmark A, Wang X, Hessner MJ (2006). Evidence of a functional role for mast cells in the development of type 1 diabetes mellitus in the BioBreeding rat. J Immunol 177:7275-7286.

Gessner A, Mohs K, Mohrs M (2005). Mast cells, basophils, and eosinophils acquire constitutive IL-4 and IL-13 transcripts during lineage differentiation that are sufficient for rapid cytokine production. J Immunol 174:1063-1072.

Ghildyal N, McNeil HP, Gurish MF, Austen KF, Stevens RL (1992a). Transcriptional regulation of the mucosal mast cellspecific protease gene, MMCP-2, by interleukin 10 and interleukin 3. J Biol Chem 267:8473-8477.

Gibbs BF, Arm JP, Gibson K, Lee TH, Pearce FL (1997). Human lung mast cells release small amounts of interleukin-4 and tumour necrosis factor-alpha in response to stimulation by anti-IgE and stem cell factor. Eur J Pharmacol 327:73-78.

Ghildyal A, Tkaczyk C (2006). Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 6:218-230.

Gibbs BF, Peavy R, Metcalfe D (2009). Amplification mechanisms for the enhancement of antigen-mediated mast cell activation. Immunol Res 43:15-24.

Gillespie SR, DeMartino RR, Zhu J, Chong HJ, Ramirez C, Shelburne CP, Bouton LA, Bailey DP, Gharse A, Mumonsef P, Odom S, Gomez G, Rivera J, Fischer-Stenger K, Ryan JJ (2004). IL-10 inhibits Fc epsilon RI expression in mouse mast cells. J Immunol 172:3181-3188.

Ginsburg H, Sachs L (1963). Formation of pure suspensions of mast cells in tissue culture by differentiation of lymphoid cells from the mouse thymus. Ann N Y Acad Sci 103:20-39.

Ginsburg H, Lagunoff D (1967). The in vitro differentiation and culture of normal mast cells from the mouse thymus. J Natl Cancer Inst 31:1-39.

Gillespie SR, DeMartino RR, Zhu J, Chong HJ, Ramirez C, Shelburne CP, Bouton LA, Bailey DP, Gharse A, Mumonsef P, Odom S, Gomez G, Rivera J, Fischer-Stenger K, Ryan JJ (2004). IL-10 inhibits Fc epsilon RI expression in mouse mast cells. J Immunol 172:3181-3188.

Ginsburg H, Lagunoff D (1967). The in vitro differentiation of mast cells. Cultures of cells from immunized mouse lymph nodes and thoracic duct lymph on fibroblast monolayers. J Cell Biol 35:685-697.

Godfraind C, Louahed J, Faulkner H, Vink A, Warnier G, Grecnis R, Renault JC (1998). Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea, and kidneys of IL-9 transgenic mice. J Immunol 160:3989-3996.
Goldstein SM, Kaempfer CE, Proud D, Schwartz LB, Irani AM, Wintroub BU (1987). Detection and partial characterization of a human mast cell carboxypeptidase. J Immunol 139:2724-2729.

Gomez G, Ramirez CD, Rivera J, Patel M, Norozian F, Wright HV, Kashyap MV, Barnstein BO, Fischer-Stenger K, Schwartz LB, Kepley CL, Ryan JJ (2005). TGF-β1 inhibits mast cell Fc epsilon RI expression. J Immunol 174:5987-5993.

Goodarzi K, Goodarzi M, Tagger AM, Luster AD, von Andrian UH (2003). Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol 4:965-973.

Gordon JR, Galli SJ (1990). Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 346:274-276.

Gottwald T, Coerper S, Schäffer M, Köveker G, Stead RH (1998). The mast cell-nerve axis in wound healing: a hypothesis. Wound Repair Regen 6:8-20.

Graham AC, Hilmer KM, Zickovich JM, Obar JJ (2013). TGF-beta 1 mediates mast cell chemotaxis. J Immunol 180:5860-5867.

Gottwald T, Coerper S, Schäffer M, Köveker G, Stead RH (1998). The mast cell-nerve axis in wound healing: a hypothesis. Wound Repair Regen 6:8-20.

Gottwald T, Coerper S, Schäffer M, Köveker G, Stead RH (1998). The mast cell-nerve axis in wound healing: a hypothesis. Wound Repair Regen 6:8-20.

Gottwald T, Coerper S, Schäffer M, Köveker G, Stead RH (1998). The mast cell-nerve axis in wound healing: a hypothesis. Wound Repair Regen 6:8-20.

Gottwald T, Coerper S, Schäffer M, Köveker G, Stead RH (1998). The mast cell-nerve axis in wound healing: a hypothesis. Wound Repair Regen 6:8-20.
Hart PH, Grimbaldeston MA, Swift GI, Jaksic A, Noonan FP, Finlay-Jones JJ (1998). Dermal mast cells determine susceptibility to ultraviolet B-induced systemic suppression of contact hypersensitivity responses in mice. J Exp Med 187:2045-2053.

Haslhofer S (1980). A hemopoietic cell line dependent upon a factor in pokeweed mitogen-stimulated spleen cell conditioning medium. J Cell Physiol 105:379-384.

Heavey DJ, Ernst PB, Stevens RL, Befus AD, Bienenstock J, AustenKF (1988). Generation of leukotriene C4, leukotriene B4, and prostaglandin D2 by immunologically activated rat intestinal mucosa mast cells. J Immunol 140:1953-1957.

Hebda PA, Collins MA, Tharp MD (1993). Mast cell and myofibroblast in wound healing. Dermatol Clin 11:685-696.

Heib V, Becker M, Warger T, Rechtsteiner G, Tertilt C, Klein M, Bopp T, Taube C, Schild H, Schmitt E, Stassen M (2007). Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice. Blood 110:946-953.

Henningsson F, Yamamoto K, Saftig P, Reinheckel T, Peters C, Knight SD, Pejler G (2005). A role for cathepsin E in the processing of mast-cell carboxypeptidase A. J Cell Sci 118:2035-2042.

Hepworth MR, Danilowicz-Luebert E, Rausch S, Metz M, Klotz C, Maurer M, Hartmann S (2012). Mast cells orchestrate type 2 immunity to helminths through regulation of tissue-derived cytokines. Proc Natl Acad Sci U S A 109:6644-6649.

Hershko AY, Suzuki R, Charles N, Alvarez-Errico D, Sargent JL, Stassen M, Denkins JE, Leder P, Besmer P (1990). The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c- receptor, the gene product of the W locus. Cell 63:225-233.

Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, Melendez AJ, McInnes IB (2010). Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 184:3336-3340.

Hu ZQ, Zhao WH, Shimamura T (2007). Regulation of mast cell development by inflammatory factors. Curr Med Chem 14:3044-3050.

Hu ZQ, Kobayashi K, Zenda N, Shimamura T (1997). Tumor necrosis factor-alpha- and interleukin-6-triggered mast cell development from mouse spleen cells. Blood 89:526-533.

Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, Liu Y, Yuan Y, Unkeless J, Xiong H, Feng ZH (2008). SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 112:1269-1279.

Huang C, Friend DS, Qiu WT, Wong GW, Morales G, Hunt J, Stevens RL (1998). Induction of a selective and persistent extravasation of neutrophils into the peritoneal cavity by tryptase mouse mast cell protease 6. J Immunol 160:1910-1919.

Huang C, Wong GW, Ghildyal N, Gurisch MF, Sali A, Matsumoto R, Qiu WT, Stevens RL (1997). The tryptase, mouse mast cell protease 7, exhibits anticoagulant activity in vivo and in vitro due to its ability to degrade fibrinogen in the presence of the diverse array of protease inhibitors in plasma. J Biol Chem 272:31885-31893.

Huang C, Morales G, Vagi A, Chanasyk K, Ferrazzi M, Burklow C, Qiu WT, Feyfant E, Sali A, Stevens RL (2000). Formation of enzymatically active, homotypic, and heterotypic tetromers of mouse mast cell tryptases. Dependence on a conserved Trp-rich domain on the surface. J Biol Chem 275:351-358.

Huang E, Nock K, Beier DR, Chu TY, Buck J, Lahm HW, Wellner D, Leder P, Besmer P (1990). The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c- receptor, the gene product of the W locus. Cell 63:225-233.

Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, Melendez AJ, McInnes IB (2010). Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 184:3336-3340.

Hu ZQ, Zhao WH, Shimamura T (2007). Regulation of mast cell development by inflammatory factors. Curr Med Chem 14:3044-3050.

Huang C, Friend DS, Qiu WT, Wong GW, Morales G, Hunt J, Stevens RL (1998). Induction of a selective and persistent extravasation of neutrophils into the peritoneal cavity by tryptase mouse mast cell protease 6. J Immunol 160:1910-1919.

Huang C, Wong GW, Ghildyal N, Gurisch MF, Sali A, Matsumoto R, Qiu WT, Stevens RL (1997). The tryptase, mouse mast cell protease 7, exhibits anticoagulant activity in vivo and in vitro due to its ability to degrade fibrinogen in the presence of the diverse array of protease inhibitors in plasma. J Biol Chem 272:31885-31893.

Huang C, Morales G, Vagi A, Chanasyk K, Ferrazzi M, Burklow C, Qiu WT, Feyfant E, Sali A, Stevens RL (2000). Formation of enzymatically active, homotypic, and heterotypic tetromers of mouse mast cell tryptases. Dependence on a conserved Trp-rich domain on the surface. J Biol Chem 275:351-358.

Huang E, Nock K, Beier DR, Chu TY, Buck J, Lahm HW, Wellner D, Leder P, Besmer P (1990). The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-receptor, the gene product of the W locus. Cell 63:225-233.

Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, Melendez AJ, McInnes IB (2010). Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 184:3336-3340.

Hu ZQ, Zhao WH, Shimamura T (2007). Regulation of mast cell development by inflammatory factors. Curr Med Chem 14:3044-3050.

Huang C, Friend DS, Qiu WT, Wong GW, Morales G, Hunt J, Stevens RL (1998). Induction of a selective and persistent extravasation of neutrophils into the peritoneal cavity by tryptase mouse mast cell protease 6. J Immunol 160:1910-1919.

Huang C, Wong GW, Ghildyal N, Gurisch MF, Sali A, Matsumoto R, Qiu WT, Stevens RL (1997). The tryptase, mouse mast cell protease 7, exhibits anticoagulant activity in vivo and in vitro due to its ability to degrade fibrinogen in the presence of the diverse array of protease inhibitors in plasma. J Biol Chem 272:31885-31893.

Huang C, Morales G, Vagi A, Chanasyk K, Ferrazzi M, Burklow C, Qiu WT, Feyfant E, Sali A, Stevens RL (2000). Formation of enzymatically active, homotypic, and heterotypic tetromers of mouse mast cell tryptases. Dependence on a conserved Trp-rich domain on the surface. J Biol Chem 275:351-358.

Huang E, Nock K, Beier DR, Chu TY, Buck J, Lahm HW, Wellner D, Leder P, Besmer P (1990). The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-receptor, the gene product of the W locus. Cell 63:225-233.

Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, Melendez AJ, McInnes IB (2010). Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 184:3336-3340.

Hu ZQ, Zhao WH, Shimamura T (2007). Regulation of mast cell development by inflammatory factors. Curr Med Chem 14:3044-3050.
Ihle JN, Peppersack L, Rebar L (1981). Regulation of T cell differentiation: in vitro induction of 20 alpha-hydroxysteroid dehydrogenase in splenic lymphocytes from athymic mice by a unique lymphokine. J Immunol 126:2184-2189.

Ihle JN, Keller J, Oroszlan S, Henderson LE, Copeland TD, Fitch F, Prystowsky MB, Goldwasser E, Schrader JW, Palazynsky E, Dy M, Lebel B (1983). Biologic properties of homonegous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity. J Immunol 131:282-287.

Ikeda RK, Miller M, Nayar J, Walker L, Cho JY, McElwain K, McElwain S, Raz E, Broide DH (2003). Accumulation of peripheral mast cells in a mouse model of ovalbumin allergen induced chronic airway inflammation: modulation by immunostimulatory DNA sequences. J Immunol 171:4860-4867.

Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB (1986). Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci U S A 83:4464-4468.

Irani AM, Craig SS, DeBlois G, Elson CO, Schechter NM, Schwartz LB (1987). Deficiency of the tryptase-positive, chymase-negative mast cell type in gastrointestinal mucosa of patients with defective T lymphocyte function. J Immunol 138:4381-4386.

Irani AM, Nilsson G, Miettinen U, Craig SS, Ashman LK, Ishizaka T, Zsebo KM, Schwartz LB (1992). Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells. Blood 80:3009-3021.

Ishii T, Fujita T, Matsumoto T, Yanaba K, Hasegawa M, Nakashima H, Ogawa F, Shimizu K, Takehara K, Tedder TF, Sato S, Fujimoto M (2009). Establishment of experimental eosinophilic vasculitis by IgE-mediated cutaneous reverse passive arthus reaction. Am J Pathol 174:2225-2233.

Ishimoto T, Arisato K, Akiiba S, Sato T (1996). Requirement of calcium influx for hydrolytic action of membrane phospholipids by cytosolic phospholipase A2 rather than mitogen-activated protein kinase activation in Fc epsilon RI-stimulated rat peritoneal mast cells. J Biochem 120:1247-1252.

Ishizaka K, Ishizaka T (1967). Identification of gamma-E-antibodies as a carrier of reaginic activity. J Immunol 99:1187-1198.

Ishizaka K, Tomioka H, Ishizaka T (1970). Mechanisms of passive sensitization. I. Presence of IgE and IgG molecules on human leukocytes. J Immunol 105:1459-1467.

Ishizaka T, Okudaira H, Mauser LE, Ishizaka K (1976). Development of rat mast cells in vitro. I. Differentiation of mast cells from thymus cells. J Immunol 116:747-754.

Ishizaka T, Adachi T, Chang TH, Ishizaka K (1977). Development of mast cells in vitro. II. Biologic function of cultured mast cells. J Immunol 118:211-217.

Ishizaka T, Chayama K, Takeda K, Hamelmann E, Terada N, Keller GM, Johnson GL, Gelfand EW (1999). Mitogen-activated protein kinase activation through Fc epsilon receptor I and stem cell factor receptor is differentially regulated by phosphatidylinositol 3-kinase and calcineurin in mouse bone marrow-derived mast cells. J Immunol 162:2087-2094.

Ito N, Sugawara K, Bodó E, Takigawa M, van Beek N, Ito T, Paus R (2010). Corticotropin-releasing hormone stimulates the in situ generation of mast cells from precursors in the human hair follicle mesenchyme. J Invest Dermatol 130:995-1004.

Iwaki S, Tkaczycz K, Satterthwaite AB, Halcomb K, Beaven MA, Metcalfe DD, Gellifan AM (2005). Bik plays a crucial role in the amplification of Fc epsilonRI-mediated mast cell activation by. J Biol Chem 280:40261-40270.

Jamur M (2005). Mastocitos. In Células. Uma Abordagem Multidisciplinar, H.F.C.C.B. Colares-Buzato, ed (São Paulo: Manole).

Jamur M, Vugman I (1988). Rat peritoneal mast cell regeneration and acid phosphatase and trimetaphosphatase activity induced after stimulation by 48/80. A fluorescence, ultrastructural, and cytochemical study. Cell Mol Biol 34:231-237.

Jamur M, Vugman I, Hand A (1986). Ultrastructural and cytochemical studies of acid phosphatase and trimetaphosphatase in rat peritoneal mast cells developing in vivo. Cell Tissue Res 244:557-563.

Jamur M, Grodski A, Berenstein E, Hamawy M, Siragian R, Oliver C (2005). Identification and characterization of undifferentiated mast cells in mouse bone marrow. Blood 105:4282-4289.

Jamur M, Grodski A, Moreno A, de Mello LF, Pastor M, Berenstein E, Siragian R, Oliver C (2001). Identification and isolation of rat bone marrow-derived mast cells using the mast cell-specific monoclonal antibody AA4. J Histochem Cytochem 49:219-228.

Jamur MC, Oliver C (2011). Origin, maturation and recruitment of mast cell precursors. Front Biosci (Schol Ed) 3:1390-1406.

Jamur MC, Moreno AN, Mello LF, Souza Júnior DA, Campos MR, Pastor MV, Grodski AC, Silva DC, Oliver C (2010). Mast cell repopulation of the peritoneal cavity: contribution of mast cell progenitors versus bone marrow derived committed mast cell precursors. BMC Immunol 11:32.

Jenne DE, Tschopp J (1991). Angiotensin II-forming heart chymase is a mast-cell-specific enzyme. Biochem J 276 ( Pt 2):567-568.

Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, Gravallese E, Mathis D, and Benoist C (2002a). Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 196:77-85.

Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, Takahashi K, Holers VM, Walport M, Gerard C, Ezekowitz A, Carroll MC, Brenner M, Weissleder R, Verbeek JS, Duchatelle V, Degott C, Benoist C, Mathis D (2002b). Arthritis critically dependent on innate immune system players. Immunity 16:157-167.

Johansson A, Rudolfsson S, Hammarsten H, Pålman S, Pietras K, Jones J, Statton P, Egevad L, Granfors T, Wikström P, Bergh A (2010). Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 177:1031-1041.

Jordan JH, Walchshofer S, Jurecka W, Mosberger I, Sperr WR, Wolff K, Chott A, Bühringer HJ, Lechner K, Horny HP, Valentin P (2001). Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-aL. Hum Pathol 32:545-552.

Jorpes E. (1935). The chemistry of heparin. Biochem J 29: 1817-1830.
Joško J, Mazurek M (2004). Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med Sci Monit 10, RA89-98.

Juczewska M, Chyczewski L (1997). Angiogenesis in cancer. Rocz Akad Med Bialymst 42 Suppl 1:86-100.

Kaartinen M, Penttilä A, Kovanes PT (1994). Accumulation of activated mast cells in the shoulder region of human corona atheroma, the predilection site of atheromatous rupture. Circulation 90:1669-1678.

Kaiédia S, Shin K, Nigrovic PA, Seki K, Lee RT, Stevens RL, Lee DM (2010). Synovial fibroblasts promote the expression and granule accumulation of tryptase via interleukin-33 and its receptor ST-2 (IL1RL1). J Biol Chem 285:21478-21486.

Kanakura Y, Kurii A, Waki N, Nakano T, Asai H, Yonezawa T, Kitamura Y (1988a). Changes in numbers and types of mast cell colony-forming cells in the peritoneal cavity of mice after injection of distilled water: evidence that mast cells suppress differentiation of bone marrow-derived precursors. Blood 71:573-580.

Kanakura Y, Thompson H, Nakano T, Yamamura T, Asai H, Kitamura Y, Metcalfe DD, Galli SJ (1988b). Multiple bidirectional alterations of phenotype and changes in proliferative potential during the in vitro and in vivo passage of clonal mast cell populations derived from mouse peritoneal mast cells. Blood 72:877-885.

Kanerva K, Lappalainen J, Mäkitie LT, Virolainen S, Kovanen PT, Andersson LC (2009). Expression of antizyme inhibitor 2 in mast cells and role of polyamines as selective regulators of serotonin secretion. PLoS One 4, e6858.

Kanwar S, Kubes P (1994). Ischemia/reperfusion-induced granulocyte influx is a multistep process mediated by mast cells. Microcirculation 1:175-182.

Karimi K, Redegeld FA, Heijdra B, Nijkamp FP (1999). Stem cell factor and interleukin-4 induce murine bone marrow cells to develop into mast cells with connective tissue type characteristics in vitro. Exp Hematol 27:654-662.

Karra L, Berent-Maoz B, Ben-Zimra M, Levi-Schaffer F (2009). Are we ready to downregulate mast cells? Curr Opin Immunol 21:708-714.

Kasugai T, Tei H, Okada M, Hirota S, Morimoto M, Yamada M, Nakama A, Arizono N, Kitamura Y (1995). Infection with Nippostrongylus brasiliensis induces invasion of mast cell precursors from peripheral blood to small intestine. Blood 85:1334-1340.

Katayama I, Yokozeki H, Nishioka K (1992). Mast-cell-derived mediators induce epidermal cell proliferation: clue for lichenified skin lesion formation in atopic dermatitis. Int Arch Allergy Immunol 98:410-414.

Katz HR, Arm JP, Benson AC, Austen KF (1990). Maturation-related changes in the expression of Fc gamma RI and Fc gamma RIII on mouse mast cells derived in vitro and in vivo. J Immunol 145:3412-3417.

Katz HR, Raizman MB, Gartner CS, Scott HC, Benson AC, Austen KF (1992). Secretory granule mediator release and generation of oxidative metabolites of arachidonic acid via Fc-IgG receptor bridging in mouse mast cells. J Immunol 148:868-871.

Katz HR, Lobell RB (1995). Expression and function of Fc gamma R in mouse mast cells. Int Arch Allergy Immunol 107:76-78.

Kauhanen P, Kovanen PT, Reunala T, Lassila R (1998). Effects of skin mast cells on bleeding time and coagulation activation at the site of platelet plug formation. Thromb Haemost 79:843-847.

Kaur D, Hollins F, Woodman L, Yang W, Monk P, May R, Bradding P, Brightling CE (2006). Mast cells express IL-13R alpha 1: IL-13 promotes human lung mast cell proliferation and Fc epsilon RI expression. Allergy 61:1047-1053.

Kawakami T, Galli SJ (2002). Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2:773-786.

Kawamoto K, Okada T, Kannan Y, Ushio H, Matsumoto M, Matsuda H (1995). Nerve growth factor prevents apoptosis of rat peritoneal mast cells through the trk proto-oncogene receptor. Blood 86:4638-4644.

Kempuraj D, Papadopoulou NG, Lytinas M, Huang M, Kandere-Grzybowska K, Madhappan B, Boucher W, Christodoulou S, Athanassiou A, Theoharides TC (2004). Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology 145:43-48.

Kennedy Norton S, Barnstein B, Brenzovich J, Bailey DP, Kashyap M, Speiran K, Ford J, Conrad D, Watowich S, Moralle MR, Kepley CL, Murray PJ, Ryan JJ (2008). IL-10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo. J Immunol 180:2848-2854.

Kiernan JA (1979). Production and life span of cutaneous mast cells in young rats. J Anat 128:225-238.

Kinet JP (1999). The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu Rev Immunol 17:931-972.

Kimoshita T, Sawai N, Hidaka E, Yamashita T, Koike K (1999). Interleukin-6 directly modulates stem cell factor-dependent development of human mast cells derived from CD34(+)+ cord blood cells. Blood 94:496-508.

Kitamura Y (1989). Heterogeneity of mast cells and phenotypic change between subpopulations. Annu Rev Immunol 7:59-76.

Kitamura Y (2000). [Growth factor, growth factor receptor and transcription factor for differentiation of mast cells]. Arerugi 49:321-323.

Kitamura Y, Go S, Hatanaka K (1978). Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52:447-452.

Kitamura Y, Shimada M, Go S (1979). Presence of mast cell precursors in fetal liver of mice. Dev Biol 70:510-514.

Kitamura Y, Shimada M, Hatanaka K, Miyano Y (1977). Development of mast cells from grafted bone marrow cells in irradiated mice. Nature 268:442-443.

Kitamura Y, Kasugai T, Arizono N, Matsuda H (1993). Development of mast cells and basophils: processes and regulation mechanisms. Am J Med Sci 306:185-191.

Kitamura Y, Sonoda T, Nakano T, Hayashi C, Asai H (1985). Differentiation processes of connective tissue mast cells in living mice. Int Arch Allergy Appl Immunol 77:144-150.

Knight PA, Wright SH, Lawrence CE, Paterson YY, Miller HR (2000). Delayed expulsion of the nematode Trichinella spiralis in mice lacking the mucosal mast cell-specific granzyme A, mouse mast cell protease-1. J Exp Med 192:1849-1856.
Lee DM, Yamasaki S, Tybulewicz VL, Saito T (2005). Rapid and large amount of autocrine IL-3 production is responsible for mast cell survival by IgE in the absence of antigen. Blood 105:2059-2065.

Kovárová M, Tolar P, Arudchodran R, Dráberová L, Rivera J, Dráber P (2001). Structure-function analysis of Lyn kinase association with lipid rafts and initiation of early signaling events after FcεRI receptor I aggregation. Mol Cell Biol 21:8318-8328.

Krokowski M, Sotlar K, Krauth MT, Födinger M, Valant P, Horny HP (2005). Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia. Am J Clin Pathol 124:560-568.

Kuehn HS, Gilfillan AM (2007). G protein-coupled receptors and the modification of FcεRI-mediated mast cell activation. Immunol Lett 113:59-69.

Kulka M, Fukushima N, Metcalfe DD (2009). Human mast cells synthesize and release angiogenin, a member of the ribonuclease A (RNase A) superfamily. J Leukoc Biol 86:1217-1226.

Kulka M, Alexopoulos O, Flavell RA, Metcalfe DD (2004). Activation of mast cells by double-stranded RNA is a novel function for human mast cells. J Allergy Clin Immunol 114:174-182.

Kumada T, Nakashima S, Nakamura Y, Miyata H, Nozawa Y (1995). Antigen-mediated phospholipase D activation in rat basophilic leukemia (RBL-2H3) cells: possible involvement of calcium/calmodulin. Biochim Biophys Acta 1258:107-114.

Kushnir-Sukhov NM, Brown JM, Wu Y, Kirshenbaum A, Metcalfe DD (2007). Human mast cells are capable of serotonin synthesis and release. J Allergy Clin Immunol 119:496-499.

Lam BK, Penrose JF, Freeman GJ, AustenKF (1994). Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc Natl Acad Sci U S A 91:7663-7667.

Lambrecht BN, De Veereman M, Coyle AJ, Gutierrez-Ramos JC, Thielemann K, Pauwels RA (2000). Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest 106:551-559.

Lantzi CS, Huff TF (1995). Murine KIT+ lineage-bone marrow progenitors express Fc gamma-RII but do not express Fc epsilon-RI until mast cell granule formation. J Immunol 154:355-362.

Lantzi CS, Boesiger J, Song CH, Mach N, Kobayashi T, Mulligan RC, Nawa Y, Dranoff G, Galli SJ (1998). Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature 392:90-93.

Leal-Berumen I, Conlon P, Marshall JS (1994). IL-6 production by rat peritoneal mast cells is not necessarily preceded by histamine release and can be induced by bacterial lipopolysaccharide. J Immunol 152:5468-5476.

Lee BP, Juvet SC, Zhang L (2009). Prostaglandin E2 signaling through E prostaglandin receptor 2 impairs proliferative response of double negative regulatory T cells. Int Immunopharmacol 9:534-539.

Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB (2002a). Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 297:1689-1692.

Lee JC, Hapel AJ, Ihle JN (1982). Constitutive production of a unique lymphokine (IL 3) by the WEHI-3 cell line. J Immunol 128:2393-2398.

Lee M, Calabresi L, Chiesa G, Franceschini G, Kovanen PT (2002b). Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 22:1475-1481.

Lee M, Kovanen PT, Tedeschi G, Ounere G, Franceschini G, Calabresi L (2003). Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux. J Lipid Res 44:539-546.

Leier I, Jedlitschky G, Buchholz U, Cole SP, Delee SY, Keppler D (1994). The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 269:27807-27810.

Leon A, Buriani A, Dal Toso R, Fabris M, Romanello S, Aloe L, Levi-Montalcini R (1994). Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci U S A 91:3739-3743.

Lesclous P, Guez D, Baroukh B, Vignery A, Saffar JL (2004). Histamine participates in the early phase of trabeclular bone loss in ovariectomized rats. Bone 34:91-99.

Lesclous P, Schramm F, Gallina S, Baroukh B, Guez D, Saffar JL (2006). Histamine mediates osteoclastic resorption only during the acute phase of bone loss in ovariectomized rats. Exp Physiol 91:561-570.

Levi-Schaffer F, Kupetzky A (1990). Mast cells enhance migration and proliferation of fibroblasts into an in vitro wound. Exp Cell Res 188:42-49.

Levi-Schaffer F, AustenKF, Gravallese PM, Stevens RL (1986). Coculture of interleukin 3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. Proc Natl Acad Sci U S A 83:6485-6488.

Li CY (2001). Diagnosis of mastocytosis: value of cytochemistry and immunohistochemistry. Leuk Res 25:537-541.

Lilla JN, Joshi RV, Craik CS, Werb Z (2009). Active plasma kalikrein localizes to mast cells and regulates epithelial cell apoptosis, adipocyte differentiation, and stromal remodeling during mammary gland involution. J Biol Chem 284:13792-13803.

Lilla JN, Chen CC, Mukai K, BenBarak MJ, Franco CB, Kalesnikoff J, Yu M, Tsai M, Piliponsky AM, Galli SJ (2011). Reduced mast cell and basophil numbers and function in Cpa3-Cre; Mcl-1fl/fl mice. Blood 118:6930-6938.

Lin AM, Rubin CJ, Khandpur R, Wang JY, Riiblett M, Yalavarthi S, Villanueva EC, Shah P, Kaplan MJ, Bruce AT (2011). Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 187:3739-3743.

Lindstedt KA, Wang Y, Shiota N, Saarinen J, Hyytiäinen M, Kokkonen JO, Kesk-Oja J, Kovanen PT (2001). Activation of paracrine TGF-beta1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase. FASEB J 15:1377-1388.

Lindstedt L, Lee M, Castro GR, Fruchart JC, Kovanen PT (1996). Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so...
reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid. J Clin Invest 97:2174-2182.
Linnekin D (1999). Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 31:1053-1074.
Liu J, Kim ML, Heo WD, Jones JT, Myers JW, Ferrell JE, Meyer T (2005). STIM is a Ca²⁺ sensor essential for Ca²⁺-store-depletion-triggered Ca²⁺ influx. Curr Biol 15:1235-1241.
Lorentz A, Bischoff SC (2001). Regulation of human intestinal mast cells by stem cell factor and IL-4. Immunol Rev 179:57-60.
Lorentz A, Klopp I, Gebhardt T, Manns MP, Bischoff SC (2003). Role of activator protein 1, nuclear factor-kappaB, and nuclear factor of activated T cells in IgE receptor-mediated cytokine expression in mature human mast cells. J Allergy Clin Immunol 111:1062-1068.
Lorentz A, Hoppe J, Worthmann H, Gebhardt T, Hesse U, Bienenstock J, Bischoff SC (2007). Neurotrophin-3, but not nerve growth factor, promotes survival of human intestinal mast cells. Neurogastroenterol Motil 19:301-308.
Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K, Scott ZA, Coyle AJ, Reed JL, Van Snick J, Strom TB, Zheng XX, Noelle RJ (2006). Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442:997-1002.
Lu R, Kanai N, Bao Y, Schuster VL (1996). Cloning, in vitro expression, and tissue distribution of a human prostat gland transporter cDNA(hPGT). J Clin Invest 98:1142-1149.
Lundequist A, Pejler G (2011). Biological implications of preformed mast cell mediators. Cell Mol Life Sci 68:965-975.
Luo X, Tarbell KV, Yang H, Pothoven K, Bailey SL, Ding R, Steinman RM, Suthanthiran M (2007). Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A 104:2821-2826.
Mahic M, Yaqub S, Johansson CC, Taskén K, Aandahl EM (2006). FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostat gland E2-dependent mechanism. J Immunol 177: 246-254.
Makibe-Kobayashi Y, Hori Y, Adachi T, Ishigaki-Suzuki S, Kikuchi Y, Kagaya Y, Shirato K, Nagy A, Ujike A, Takai T, Watanabe T, Ohtsu H (2002). The control effect of histamine on body temperature and respiratory function in IgE-mediated cytokine production on nuclear factor-kappaB activity. J Allergy Clin Immunol 105:500-505.
Malbec O, Duéron M (2007). The mast cell IgG receptors and their roles in tissue inflammation. Immunol Rev 217:206-221.
Malbec O, Fong DC, Turner M, Tybuliewicz VL, Cambier JC, Fridman WH, Daéron M (1998). Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIb during negative regulation of mast cell activation. J Immunol 160:1647-1658.
Malby S, Khazaie K, McNagny KM (2009). Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 1796:19-26.
Marquardt DL, Walker LL (2000). Dependence of mast cell IgE-mediated cytokine production on nuclear factor-kappaB activity. J Allergy Clin Immunol 105:500-505.
Marshall JS (2004). Mast-cell responses to pathogens. Nat Rev Immunol 4:787-799.
Marshall JS, King CA, McCurdy JD (2003). Mast cell cytokine and chemokine responses to bacterial and viral infection. Curr Pharm Des 9:11-24.
Marshall JS, Leal-Berumen I, Nielsen L, Gibetic M, Jordana M (1996). Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. J Clin Invest 97:1122-1128.
Masuda A, Yoshikai Y, Aiba K, Matsuguchi T (2002). Th2 cytokine production from mast cells is directly induced by lipopolysaccharide and distinctly regulated by c-Jun N-terminal kinase and p38 pathways. J Immunol 169:3801-3810.
Masuda A, Matsuguchi T, Yamaki K, Hayakawa T, Yoshikai Y (2001). Interleukin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-xl expression. J Biol Chem 276:26107-26113.
Masuda A, Matsuguchi T, Yamaki K, Hayakawa T, Kubo M, LaRochelle WJ, Yoshikai Y (2000). Interleukin-15 induces rapid tyrosine phosphorylation of STAT6 and the expression of interleukin-4 in mouse mast cells. J Biol Chem 275:29331-29337.
Matsuda H, Kannan Y, Ushio H, Kiso Y, Kanemoto T, Suzuki H, Kitamura Y (1991). Nerve growth factor induces development of connective tissue-type mast cells in vitro from murine bone marrow cells. J Exp Med 174:7-14.
Matsuda H, Koyama H, Sato H, Sawada J, Itakura A, Tanaka A, Matsumoto M, Komuro K, Ushio H, Matsuda K (1998). Role of nerve growth factor in cutaneous wound healing: accelerating effects in normal and healing-impaired diabetic mice. J Exp Med 187:297-306.
Matsumoto I, Staub A, Benoist C, Mathis D (1999). Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286:1732-1735.
Matsuzawa S, Sakashita K, Kinoshita T, Ito S, Yamashita S, Koike T (2003). IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol 170:3461-3467.
Maurer M, Paus R, Czarnetzki BM (1995). Mast cells as modulators of hair follicle cycling. Exp Dermatol 4:266-271.
Maurer M, Wedemeyer J, Metz M, Piliponsky AM, Weller K, Chatterjee D, Clouthier DE, Yanagisawa MM, Tsai M, Galli SJ (2004). Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 432:512-516.
Maurer M, Theoharides T, Granstein RD, Bischoff SC, Bienenstock J, Henz B, Kovánen P, Piliponsky AM, Kambe N, Vilagòtis H, Levi-Schaffer F, Metz M, Miyachi Y, Befus D, Forsythe P, Kitamura Y, Galli S (2003). What is the physiological function of mast cells? Exp Dermatol 12:886-910.

Maxová H, Bačáková L, Lisá V, Novotná J, Tomášová H, Vízek M, Herget J (2010). Production of proteolytic enzymes in mast cells, fibroblasts, vascular smooth muscle and endothelial cells cultivated under normoxic or hypoxic conditions. Physiol Res 59:711-719.

McGlade JP, Gorman S, Zosky GR, Larcombe AN, Sly PD, Finlay-Jones JJ, Turner DJ, Hart PH (2007). Suppression of the asthmatic phenotype by ultraviolet B-induced, antigen-specific regulatory cells. Clin Exp Allergy 37:1267-1276.

McIlroy A, Caron G, Blanchard S, Frémaux I, Duluc D, Delneste Y, Chevailler A, Jeannin P (2006). Histamine and prostaglandin E up-regulate the production of Th2-attracting chemokines (CCL17 and CCL22) and down-regulate IFN-gamma-induced CXCL10 production by immature human dendritic cells. Immunology 117:507-516.

McNeil HP, Shin K, Campbell IK, Wicks IP, Adachi R, Lee DM, Stevens RL (2008). The mouse mast cell-restricted tetramer-forming tryptases mouse mast cell protease 6 and mouse mast cell protease 7 are critical mediators in inflammatory arthritis. Arthritis Rheum 58:2338-2346.

Medvinsky A, Dzierzak E (1996). Definitive hematopoiesis is autonomously initiated by the AGM region. Cell 86:897-906.

Medvinsky A, Rybtsou S, Taoudi S (2011). Embryonic origin of the adult hematopoietic system: advances and questions. Development 138:1017-1031.

Meininger CJ, Zetter BR (1992). Mast cells and angiogenesis. Semin Cancer Biol 3:73-79.

Mekori YA, Galli SJ (1990). [125I]fibrin deposition occurs at both early and late intervals of IgE-dependent or contact sensitivity reactions elicited in mouse skin. Mast cell-dependent augmentation of fibrin deposition at early intervals in combined IgE-dependent and contact sensitivity reactions. J Immunol 145:3719-3727.

Mellon MB, Frank BT, Fang KC (2002). Mast cell alpha-chymase reduces IgE recognition of birch pollen protein by cleaving antibody-binding epitopes. J Immunol 168:290-297.

Melo FR, Waern I, Rönb erg E, Abrink M, Lee DM, Schlenner SM, Feyerabend TB, Rodewald HR, Turk B, Wernerson S, Pejler G (2011). A role for serglycin proteoglycan in mast cell apoptosis induced by a secretory granule-mediated pathway. J Biol Chem 286:5423-5433.

Mendonça VO, Vugman I, Jamur MC (1986). Maturation of adult rat peritoneal and mesenteric mast cells. A morphological and histofluorescence study. Cell Tissue Res 243:635-639.

Metcalfe D (1986). The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood 67:257-267.

Metcalfe D (2008). Mast cells and mastocytosis. Blood 112:946-956.

Metcalfe D, Boyce J (2006). Mast cell biology in evolution. J Allergy and Clin Immunol 117:1227-1229.

Metcalfe D, Baram D, Mekori Y (1997). Mast cells. Physiol Reviews 77:1033-1079.

Metcalfe DD, Peavy RD, Gilfillan AM (2009). Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol 124:639-646; quiz 647-638.

Metcalfe DD, Lewis RA, Silbert JE, Rosenberg RD, Wasserman SI, Austen KF (1979). Isolation and characterization of heparin from human lung. J Clin Invest 64:1337-1543.

Metz M, Siebenhaar F, Maurer M (2008). Mast cell functions in the innate skin immune system. Immunobiology 213:251-260.

Metz M, Botschkarev VA, Botschkareva NV, Welker P, Tobin DJ, Knop J, Maurer M, Paus R (2004). Neurotrophin-3 regulates mast cell functions in neonatal mouse skin. Exp Dermatol 13:273-281.

Metz M, Piliponsky AM, Chen CC, Lammel V, Abrink M, Pejler G, Tsaí M, Galli SJ (2006). Mast cells can enhance resistance to snake and honeybee venoms. Science 313:526-530.

Metzger H (1992). The receptor with high affinity for IgE. Immunol Rev 125:37-48.

Middel P, Reich K, Polzien F, Blaschke V, Hemmerlein B, Herms J, Korabiowska M, Radzun HJ (2001). Interleukin 16 expression and phenotype of interleukin 16 producing cells in Crohn’s disease. Gut 49:795-803.

Miettinen M, Lasota J (2005). KIT (CD117): a review on expression and phenotype of interleukin 16 producing cells in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 13:205-220.

Miller HR, Pemberton AD (2002). Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut. Immunology 105:375-390.

Miller HR, Wright SH, Knight PA, Thornton EM (1999). A novel function for transforming growth factor-beta1: upregulation of the expression and the IgE-independent extracellular release of a mucosal mast cell granule-specific beta-chymase, mouse mast cell protease-1. Blood 93:3473-3486.

Mirmansof P, Shelburne CP, Fitzhugh Yeatman C, Chong HJ, Ryan JJ (1999). Inhibition of Kit expression by IL-4 and IL-10 in murine mast cells: role of STAT6 and phosphatidylinositol 3'-kinase. J Immunol 163:2530-2539.

Montesano R, Orci L, Vassalli P (1983). In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 97:1648-1652.

Moon TC, St Laurent CD, Morris KE, Marcet C, Yoshimura T, Sekar Y, Befus AD (2010). Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol 3:111-128.

Moreno A, Jamur M, Oliver C, Roque-Barreira M (2003). Mast cell degranulation induced by lectins: effect on neutrophil recruitment. Int Arch Allergy Immunol 132:221-230.

Moulin V (1995). Growth factors in skin wound healing. Eur J Cell Biol 68:1-7.

Moulin V, Castilhox G, Auger FA, Garrel D, O’Connor-McCourt MD, Germain L (1998). Modulated response to cytokines of human wound healing myofibroblasts compared to dermal fibroblasts. Exp Cell Res 238:283-293.

Müller AM, Medvinsky A, Strouboulis J, Grosveld F, Dzierzak E (1994). Development of hematopoietic stem cell activity in the mouse embryo. Immunity 1:291-301.

Murakami M, Matsumoto R, Austen KF, Arm JP (1994). Prostaglandin endoperoxide synthase-1 and -2 couple to different...
transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells. J Biol Chem 269:22269-22275.

Muramatsu M, Katada J, Hayashi I, Majima M (2000a). Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. J Biol Chem 275:5545-5552.

Muramatsu M, Katada J, Hattori M, Hayashi I, Majima M (2000b). Chymase mediates mast cell-induced angiogenesis in hamster sponge granulomas. Eur J Pharmacol 402:181-191.

Musio S, Gallo B, Scabeni S, Lapilla M, Poliani PL, Matarese G, Ohtsu H, Galli SJ, Mantegazza R, Steinman L, Pedotti R (2006). A key regulatory role for histamine in experimental autoimmune encephalomyelitis: disease exacerbation in histidine decarboxylase-deficient mice. J Immunol 176:17-26.

Nabel G, Galli SJ, Dvorak AM, Dvorak HF, Cantor H (1981). Inducer T lymphocytes synthesize a factor that stimulates proliferation of cloned mast cells. Nature 291:332-334.

Nagao K, Yokoro K, Aaronson SA (1981). Continuous lines of basophil/mast cells derived from normal mouse bone marrow. Science 212:333-335.

Nagasaka A, Matsue H, Matsushima H, Aoki R, Nakamura Y, Kambe N, Kon S, Uede T, Shimada S (2008). Osteopontin is produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. Eur J Immunol 38:489-499.

Nakae S, Suto H, Kakurati M, Sedgwick JD, Tsai M, Galli SJ (2005). Mast cells enhance T cell activation: Importance of mast cell-derived TNF. Proc Natl Acad Sci U S A 102:6467-6472.

Nakae S, Suto H, Ikura M, Kakurati M, Sedgwick JD, Tsai M, Galli SJ (2006). Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 176:2238-2248.

Nakahata T, Kobayashi T, Ishiguro A, Tsuji K, Naganuma K, Ando O, Yagi Y, Tadokoro K, Akabane T (1986). Extensive proliferation of mature connective-tissue type mast cells in vitro. Nature 324:65-67.

Nakano N, Nishiyama M, Okajima T, Nakamura M, Aozasa K, Okuyama A (2007). Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br J Cancer 97:952-956.

Norby K (2002). Mast cells and angiogenesis. AP Mis 110:355-371.

Ochi H, Hirani WM, Yuan Q, Friend DS, Austen FK, Boyce JA (1999). T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med 190:267-280.

Ogawa K, Nabe T, Yamamura H, Kohno S (1999). Nanomolar concentrations of neuropeptides induce histamine release from peritoneal mast cells of a strain of Wistar rats. Eur J Pharmacol 374:285-291.

Okhuda H (2008). Progress in allergy signal research on mast cells: the role of histamine in immunological and cardiovascular disease and the transporting system of histamine in the cell. J Pharmacol Sci 106:347-353.

Okayama Y, Kawakami T (2006). Development, migration, and survival of mast cells. Immunol Res 34:97-115.

Okayama Y, Kimura M, Hageman DD, Metcalfe DD (2000). Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: Up-regulation by IFN-gamma. J Immunol 164:4332-4339.

Okayama Y, Hagaman DD, Metcalfe DD (2001a). A comparison of mediators released or generated by IFN-gamma-treated human mast cells following aggregation of Fc gamma RI or Fc epsilon RI. J Immunol 166:4705-4712.

Okayama Y, Hagaman DD, Woolhiser M, Metcalfe DD (2001b). Further characterization of FegammaRII and FegammaRIII expression by cultured human mast cells. Int Arch Allergy Immunol 124:155-157.
Owyang AM, Tkaczyk C, Metcalfe DD, Gilfillan AM (2003). Comparison of Fc epsilon RI- and Fc gamma RI-mediated degranulation and TNF-alpha synthesis in human mast cells: selective utilization of phosphatidylinositol-3-kinase for Fc gamma RI-induced degranulation. Eur J Immunol 33:1450-1459.

Oldford SA, Haidl ID, Howatt MA, Leiva CA, Johnston B, Marshall JS (2010). A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. J Immunol 185:7067-7076.

Olsson N, Piek E, ten Dijke P, Nilsson G (2000). Human mast cell migration in response to members of the transforming growth factor-beta family. J Leukoc Biol 67:350-356.

Olsson N, Piek E, Sundström M, ten Dijke P, Nilsson G (2001). Transforming growth factor-beta-mediated mast cell migration depends on mitogen-activated protein kinase activity. Cell Signal 13:483-490.

Orfao A, Garcia-Montero AC, Sanchez L, Escribano L, REMA (2007). Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 138:12-30.

Orinska Z, Bulanova E, Budagian V, Metz M, Maurer M, Bulfone-Paus S (2005). TLR3-induced activation of mast cells modulates CD8+ T-cell recruitment. Blood 106:978-987.

Orinska Z, Maurer M, Mirghomizadeh F, Bulanova E, Metz M, Nashkevich N, Schieman K, Schumistrat J, Budagian V, Giron-Michel J, Brandt E, Raus P, Bulfone-Paus S (2007). IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activity. Nat Med 13:927-934.

Orr EL (1988). Presence and distribution of nervous system-associated mast cells that may modulate experimental autoimmune encephalomyelitis. Ann N Y Acad Sci 540:723-726.

Oskeritzian CA, Zhao W, Min HK, Xia HZ, Pozez A, Kiev J, Schwartz LB (2005). Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell. J Allergy Clin Immunol 115:1162-1168.

Oskeritzian CA, Wang Z, Kochan JP, Grimes M, Du Z, Chang HW, Grant S, Schwartz LB (1999). Recombinant human (rh)IL-4-mediated apoptosis and recombinant human IL-6-mediated protection of recombinant human stem cell factor-dependent human mast cells derived from cord blood mononuclear cell progenitors. J Immunol 163:5105-5115.

Otsu K, Nakano T, Kanakura Y, Asai H, Katz HR, Austen KF, Stevens RL, Galli SJ, Kitamura Y (1987). Phenotypic changes of bone marrow-derived mast cells after intraperitoneal transfer into W/Wv mice that are genetically deficient in mast cells. J Exp Med 165:615-627.

Otsuka A, Kubo M, Honda T, Egawa G, Nakajima S, Tanizaki H, Kim B, Matsuoka S, Watanabe T, Nakae S, Miyachi Y, Kabashima K (2011). Requirement of interaction between mast cells and skin dendritic cells to establish contact hyper-responsiveness. PLoS One 6, e25538.3

Ott V, Cambier J (2000). Activating and inhibitory signaling in mast cells: new opportunities for therapeutic intervention? J Allergy Clin Immunol 106:429-440.

Owyang AM, Zaph C, Wilson EH, Guild KJ, McClanahan T, Miller HR, Cua DJ, Goldschmidt M, Hunter CA, Kastelein RA, Artis D (2006). Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med 203:843-849.

Ozawa K, Szallasi Z, Kazanietz MG, Blumberg PM, Mischak H, Mushinsky JF, Beaven MA (1993). Ca(2+)-dependent and Ca(2+)-independent isozymes of protein kinase C mediate exocytosis in antigen-stimulated rat basophilic RBL-2H3 cells. Reconstitution of secretory responses with Ca(2+) and purified isozymes in washed permeabilized cells. J Biol Chem 268:1749-1756.

Palis J, Robertson S, Kennedy M, Wall C, Keller G (1999). Development of erythroid and myeloid progenitors in the yolk sac and embryo proper of the mouse. Development 126:5075-5084.

Pang L, Nie M, Corbett L, Sutcliffe A, Knox AJ (2006). Mast cell beta-tryptase selectively cleaves eotaxin and RANTES and abrogates their eosinophil chemotactic activities. J Immunol 176:3788-3795.

Pardanani A (2012). Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management. Am J Hematol 87:401-411.

Parikh SA, Cho SH, Oh CK (2003). Preformed enzymes in mast cell granules and their potential role in allergic rhinitis. Curr Allergy Asthma Rep 3:266-272.

Patella V, de Crescenzo G, Ciccarelli A, Marinò I, Adt M, Marone G (1995). Human heart mast cells: a definitive case of mast cell heterogeneity. Int Arch Allergy Immunol 106:386-393.

Pejler G, Abrink M, Wernersson S (2009). Serylglucine proteoglycan: regulating the storage and activities of hematopoietic proteases. Biofactors 35:61-68.

Pejler G, Rönnberg E, Waern I, Wernersson S (2010). Mast cell proteases: multifaceted regulators of inflammatory disease. Blood 115:4981-4990.

Pelletier C, Varin-Blank N, Rivera J, Iannascoli B, Marchand F, David B, Weyer A, Blank U (1998). Fc epsilonRI-mediated induction of TNF-alpha gene expression in the RBL-2H3 mast cell line: regulation by a novel NF-kappaB-like nuclear binding complex. J Immunol 161:4768-4776.

Pennock JL, Grencis RK (2004). In vivo exit of c-/+CD49d(hi)/beta7+ mucosal mast cell precursors from the bone marrow following infection with the intestinal nematode Trichinella spiralis. Blood 103:2655-2660.

Peters SP, MacGlashan DW, Schulman ES, Schleimer RP, Hayes EC, Rokach J, Adkinson NF, Lichtenstein LM (1984). Arachidonic acid metabolism in purified human lung mast cells. J Immunol 132:1972-1979.

Piconese S, Gri G, Tripodo C, Musio S, Gorzanelli A, Frossi B, Pedotti R, Pucillo CE, Colombo MP (2009). Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood 114:2639-2648.

Piliponsky AM, Chen CC, Nishimura T, Metz M, Rios EJ, Dobner EC, Wada E, Wada K, Zacharias S, Mohanasundaram UM, Faix JD, Abrink M, Pejler G, Pearl RG, Tsai M, Galli SJ (2008). Neutrotoxin increases mortality and mast cells reduce neutrotoxin levels in a mouse model of sepsis. Nat Med 14:392-398.

Poncet P, Arock M, David B (1999). MHC class II-dependent activation of CD4+ T cell hybridomas by human mast cells through superantigen presentation. J Leukoc Biol 66:105-112.
Pongor É, Altdorfer K, Fehér E (2011). Colocalization of substance P with tumor necrosis factor-α in the lymphocytes and mast cells in gastritis in experimental rats. Inflamm Res 60:163-168.

Prausnitz C, Kustner H (1921). Studien über die Uberempfindlichkeit. Ztbl Bakt Parasakt Abt 86:160-169.

Qi JC, Stevens RL, Wadley R, Collins A, Cooley M, Naif HM, Nasr N, Cunningham A, Katsoulotos G, Wanigasek Y, Roufogalis B, Krilis SA (2002). IL-16 regulation of human mast cells/basophils and its susceptibility to HIV-1. J Immunol 168:4127-4134.

Qi JC, Stevens RL, Wadley R, Collins A, Cooley M, Naif HM, Nasr N, Cunningham A, Katsoulotos G, Wanigasek Y, Roufogalis B, Krilis SA (2002). IL-16 regulation of human mast cells/basophils and its susceptibility to HIV-1. J Immunol 168:4127-4134.

Qi JC, Stevens RL, Wadley R, Collins A, Cooley M, Naif HM, Nasr N, Cunningham A, Katsoulotos G, Wanigasek Y, Roufogalis B, Krilis SA (2002). IL-16 regulation of human mast cells/basophils and its susceptibility to HIV-1. J Immunol 168:4127-4134.

Qi JC, Stevens RL, Wadley R, Collins A, Cooley M, Naif HM, Nasr N, Cunningham A, Katsoulotos G, Wanigasek Y, Roufogalis B, Krilis SA (2002). IL-16 regulation of human mast cells/basophils and its susceptibility to HIV-1. J Immunol 168:4127-4134.

Qi JC, Stevens RL, Wadley R, Collins A, Cooley M, Naif HM, Nasr N, Cunningham A, Katsoulotos G, Wanigasek Y, Roufogalis B, Krilis SA (2002). IL-16 regulation of human mast cells/basophils and its susceptibility to HIV-1. J Immunol 168:4127-4134.

Qi JC, Stevens RL, Wadley R, Collins A, Cooley M, Naif HM, Nasr N, Cunningham A, Katsoulotos G, Wanigasek Y, Roufogalis B, Krilis SA (2002). IL-16 regulation of human mast cells/basophils and its susceptibility to HIV-1. J Immunol 168:4127-4134.
development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice. J Immunol 161:6463-6467.

Rothschild AM, Schayer RW (1959). Characterization of histidine decarboxylase from rat peritoneal fluid mast cells. Biochim Biophys Acta 34:392-396.

Rozniecki JJ, Hauser SL, Stein M, Lincoln R, Theoharides TC (1995). Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 37:63-66.

Rubinchik E, Norris A, Levi-Schaffer F (1995). Modulations of histamine release from mast cells by interleukin-2 is affected by nedocromil sodium. Int J Immunopharmacol 17:563-570.

Ruitenbeek EJ, Elgersma A (1979). Absence of intestinal mast cell response in congenitally athymic mice during Trichinella spiralis infection. Nature 264:258-260.

Rumsaeng V, Cruikshank WW, Foster B, Prusin C, Kirshenbaum AS, Davis TA, Kornfeld H, Center DM, Metcalfe DD (1997). Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16. J Immunol 159:2904-2910.

Russell ES (1979). Hereditary anemias of the mouse: a review for geneticists. Adv Genet 20:357-459.

Ryan JJ, DeSimone S, Klisch G, Shelburne C, McReynolds LJ, Han K, Kovacs R, Mirrmonsef P, Huff TF (1998). IL-4 inhibits mouse mast cell Fc epsilonRI expression through a STAT6-dependent mechanism. J Immunol 161:6915-6923.

Ryan JJ, Kashyap M, Bailey D, Kennedy S, Speiran K, Brenzovich J, Barnstein O, Oskeritzian C, Gomez G (2007). Mast cell homeostasis: a fundamental aspect of allergic disease. Crit Rev Immunol 27:15-32.

Rönnberg E, Pejler G (2012). Serglycin: the master of the mast cell. Methods Mol Biol 836:201-217.

Rönnberg E, Calounova G, Pejler G (2011). Mast cells express tyrosine hydroxylase and store dopamine in a serglycin-dependent manner. Biol Chem.

Saini SS, Patermiti M, Vasagar K, Gibbons SP, Sterba PM, Vonakis BM (2009). Cultured peripheral blood mast cells from chronic idiopathic urticaria patients spontaneously degranulate upon IgE sensitization: Relationship to expression of Syk and SHIP-2. Clin Immunol 132:342-348.

Saito K, Ebisawa M, Tachimoto H, Shichijo M, Fukagawa K, Matsumoto K, Ikura Y, Awaji T, Tsujimoto G, Yanagida M, Uzumaki H, Takahashi G, Tsuji K, Nakahata T (1996). Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J Immunol 157:343-350.

Sagayar Y, Wang KY, Tanimoto A, Tsutsui M, Ueno H, Murata Y, Kohno Y, Yamada S, Ohtsu H (2005). Role of histamine produced by bone marrow-derived vascular cells in pathogenesis of atherosclerosis. Cire Res 96:974-981.

Sawatubasai M, Yamada T, Fukushima N, Mizokami H, Tokunaga O, Shin T (2000). Association of vascular endothelial growth factor and mast cells with angiogenesis in laryngeal squamous cell carcinoma. Virchows Arch 436:243-248.

Sayed B, Christy A, Quirion M, Brown M (2008). The master switch: the role of mast cells in autoimmunity and tolerance. Annu Rev Immunol 26:705-739.

Scanduzzi L, Beghadi W, Daugas E, Abrink M, Tiwari N, Brochetta C, Claver J, Arouche N, Zang X, Pretolani M, Monteiro RC, Pejler G, Blank U (2010). Mouse mast cell protease-4 deteriorates renal function by contributing to inflammation and fibrosis in immune complex-mediated glomerulonephritis. J Immunol 185:624-633.

Schneider E, Pollard H, Lepault F, Guy-Grand D, Minkowski M, Dy M (1987). Histamine-producing cell-stimulating activity. Interleukin 3 and granulocyte-macrophage colony-stimulating factor induce de novo synthesis of histidine decarboxylase in hemopoietic progenitor cells. J Immunol 139:3710-3717.

Schneider LA, Schlenner SM, Feyerabend TB, Wunderlin M, Rodewald HR (2007). Molecular mechanism of mast cell mediated innate defense against endothelin and snake venom sarafotoxin. J Exp Med 204:2629-2639.

Schrader JW (1981). In vitro production and cloning of the P cell, a bone marrow-derived null cell that expresses H-2 and Ia-antigens, has mast cell-like granules, and is regulated by a factor released by activated T cells. J Immunol 126:452-458.

Schwartz LB, Austen KF (1980). Enzymes of the mast cell granule. J Invest Dermatol 74:349-353.

Schwartz LB, Lewis RA, Seldin D, Austen KF (1981). Acid hydrolases and tryptase from secretory granules of dispersed human lung mast cells. J Immunol 126:1290-1294.

Schwartz LB, Irani AM, Roller K, Castells MC, Schechter NM (1987). Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J Immunol 138:2611-2615.

Schwartz LB (2006). Analysis of MC(T) and MC(TC) mast cells in tissue. Methods Mol Biol 315:53-62.

Schäffer M, Beiter T, Becker HD, Hunt TK (1998). Neuropeptides: mediators of inflammation and tissue repair? Arch Surg 133:1107-1116.

Secor VH, Secor WE, Gutekunst CA, Brown MA (2000). Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med 191:813-822.

Seelkreyers P, Yasuda P, Weiner H, Johnson D (1989). Treatment Of Experimental Allergic Neuritis With Nedocromil Sodium. Journal of Neuroimmunology 25:221-226.

Shaulian E, Karin M (2002). AP-1 as a regulator of cell life and death. Nat Cell Biol 4, E131-136.

Shefler I, Salamon P, Hershko AY, Mekori YA (2011). Mast cells as sources and targets of membrane vesicles. Curr Pharm Des 17:3797-3804.

Shik D, Munitz A (2010). Regulation of allergic inflammatory responses by inhibitory receptors. Clin Exp Allergy 40:700-709.

Shimizu Y, Matsumoto K, Okayama Y, Sakai K, Maeno T, Suga T, Miura T, Takai S, Karabayashi M, Saito H (2008). Interleukin-3 does not affect the differentiation of mast cells derived from human bone marrow progenitors. Immuno Invest 37:1-17.

Shin K, Watts GF, Oettgen HC, Friend DS, Pemberton AD, Gurish MF, Lee DM (2008). Mouse mast cell tryptase mMCP-6 is a critical link between adaptive and innate immunity in the
chronic phase of Trichinella spiralis infection. J Immunol 180:4885-4891.

Sillaber C, Strobl H, Bevec D, Ashman FK, Butterfield JH, Lechner K, Maurer D, Bettelheim P, Valentin P (1991). IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol 147:4224-4228.

Silver RB, Reid AC, Mackins CJ, Awschalom T, Schaefler U, Herzlzinger D, Levi R (2004). Mast cells: a unique source of retnin. Proc Natl Acad Sci U S A 101:13607-13612.

Simon T, László V, Falus A (2011). Impact of histamine on dendritic cell functions. Cell Biol Int 35:997-1000.

Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S (2007). Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67:4507-4513.

Siraganian R (2003). Mast cell signal transduction from the high-affinity IgE receptor. Current Opinion in Immunology 15:639-646.

Skokos D, Botros HG, Demeure C, Morin J, Peronet R, Birkenmeier G, Boudaly S, Méchéri S (2003). Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J Immunol 170:3037-3045.

Smith R, Ransjö M, Tatarczuch L, Song SJ, Pagel C, Morrison JR, Pike RN, Mackie EJ (2004). Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation. J Bone Miner Res 19:507-516.

Sonoda S, Sonoda T, Nakano T, Kanayama Y, Kanakura Y, Asai H, Yonezawa T, Kitamura Y (1986). Development of mucosal mast cells after injection of a single connective tissue matrix mast cell in the stomach mucosa of genetically mast cell-deficient W/Wv mice. J Immunol 137:1319-1322.

Sonoda T, Hayashi C, Kitamura Y (1983). Presence of mast cell precursors in the yolk sac of mice. Dev Biol 97:89-94.

Sonoda T, Kanayama Y, Hara H, Hayashi C, Tadokoro M, Yonezawa T, Kitamura Y (1984). Proliferation of peritoneal mast cells in the skin of W/Wv mice that genetically lack mast cells. J Exp Med 160:138-151.

Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P (2004). CD25 indicates the neoplastic phenotype of mast cells and neurites. Biol Pharm Bull 27:1891-1894.

Supajatura V, Ushio H, Nakao A, Okumura K, Ra C, Ogawa H (2001). Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J Immunol 167:2250-2256.

Supajatura V, Ushio H, Nakao A, Akira S, Okumura K, Ra C, Ogawa H (2002). Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 109:1351-1359.

Sutherland RE, Olsen JS, McKinnstry A, Villalta SA, Wolters PJ (2008). Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing. J Immunol 181:5598-5605.

Suto H, Nakae S, Kakurai M, Sedgwick JD, Tsai M, Galli SJ (2006). Mast cell-associated TNF promotes dendritic cell migration. J Immunol 176:4102-4112.

Suzuki A, Suzuki R, Funuro T, Teshima R, Nakanishi M (2004). N-cadherin plays a role in the synapse-like structures between mast cells and neurites. Biol Pharm Bull 27:1891-1894.

Suzuki R, Funuro T, McKay DM, Wolvers D, Teshima R, Nakanishi M, Bienenstock J (1999). Direct neurite-mast cell communication in vitro occurs via the neuropeptide substance P. J Immunol 163:2410-2415.

Swindle EJ, Metcalfe DD (2007). The role of reactive oxygen species and nitric oxide in mast cell-dependent inflammatory processes. Immunol Rev 217:186-205.

Sá-Nunes A, Bafica A, Lucas DA, Conrads TP, Veenstra TD, Andersen JF, Mather TN, Ribeiro JM, Francischetti IM (2007). Prostaglandin E2 is a major inhibitor of dendritic cell maturation and function in Ixodes scapularis saliva. J Immunol 179:1497-1505.

Sörbo J, Jakobsson A, Norrbry K (1994). Mast-cell histamine is angiogenic through receptors for histamine1 and histamine2. Int J Exp Pathol 75:43-50.

Takanami I, Takeuchi K, Naruke M (2000). Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 88:2686-2692.

Steinman L (2001). Multiple sclerosis: a two-stage disease. Nat Immunol 2:762-764.

Stelekati E, Bahi R, D’Orlando O, Orinska Z, Mittrücker HW, Langenhauzen R, Glatzel M, Bollinger A, Paus R, Bulfone-Paus S (2009). Mast cell-mediated antigen presentation regulates CD8+ T cell effector functions. Immunity 31:665-676.

Stevens RL, Friend DS, McNeil HP, Schiller V, Ghildyal N, Austen KF (1994). Strain-specific and tissue-specific expression of mouse mast cell secretory granule proteases. Proc Natl Acad Sci U S A 91:128-132.

Stevens RL, Adachi R (2007). Protease-proteoglycan complexes of mouse and human mast cells and importance of their beta-tryptase-heparin complexes in inflammation and innate immunity. Immunol Rev 217:155-167.

Sun J, Zhang J, Lindholt JS, Sukhova GK, Liu J, He A, Abrink M, Pelger G, Stevens RL, Thompson RW, Ennis TL, Gurish M, Libby P, Shi GP (2009). Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation 120:973-982.

Sundstrom JB, Ellis JE, Hair GA, Kirshenbaum AS, Metcalfe DD, Yi H, Cardona AC, Lindsay MK, Ansari AA (2007). Human tissue mast cells are an inducible reservoir of persistent HIV infection. Blood 109:5293-5300.

Sugiyama T, Ushio H, Nakao A, Okumura K, Ra C, Ogawa H (2001). Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J Immunol 167:2250-2256.

Sugiyama V, Ushio H, Nakao A, Akira S, Okumura K, Ra C, Ogawa H (2002). Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 109:1351-1359.

Sutherland RE, Olsen JS, McKinnistry A, Villalta SA, Wolters PJ (2008). Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing. J Immunol 181:5598-5605.

Suto H, Nakae S, Kakurai M, Sedgwick JD, Tsai M, Galli SJ (2006). Mast cell-associated TNF promotes dendritic cell migration. J Immunol 176:4102-4112.

Suzuki A, Suzuki R, Funuro T, Teshima R, Nakanishi M (2004). N-cadherin plays a role in the synapse-like structures between mast cells and neurites. Biol Pharm Bull 27:1891-1894.

Suzuki R, Funuro T, McKay DM, Wolvers D, Teshima R, Nakanishi M, Bienenstock J (1999). Direct neurite-mast cell communication in vitro occurs via the neuropeptide substance P. J Immunol 163:2410-2415.

Swindle EJ, Metcalfe DD (2007). The role of reactive oxygen species and nitric oxide in mast cell-dependent inflammatory processes. Immunol Rev 217:186-205.

Sá-Nunes A, Bafica A, Lucas DA, Conrads TP, Veenstra TD, Andersen JF, Mather TN, Ribeiro JM, Francischetti IM (2007). Prostaglandin E2 is a major inhibitor of dendritic cell maturation and function in Ixodes scapularis saliva. J Immunol 179:1497-1505.

Sörbo J, Jakobsson A, Norrbry K (1994). Mast-cell histamine is angiogenic through receptors for histamine1 and histamine2. Int J Exp Pathol 75:43-50.

Takanami I, Takeuchi K, Naruke M (2000). Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 88:2686-2692.
Talreja J, Kabir MH, B Filla M, Stechschulte DJ, Dileepan KN (2004). Histamine induces Toll-like receptor 2 and 4 expression in endothelial cells and enhances sensitivity to Gram-positive and Gram-negative bacterial cell wall components. Immunology 113:224-233.

Taub D, Dastych J, Inamura N, Upton J, Kelvin D, Metcalfe D, Oppenheim J (1995). Bone marrow-derived murine mast cells migrate, but do not degranulate, in response to chemokines. J Immunol 154:2393-2402.

Taylor BC, Zaph C, Troy AE, Du Y, Guild KJ, Comeau MR, Artis D (2009). TSLP regulates intestinal immunity and inflammation in mouse models of helminth infection and colitis. J Exp Med 206:655-667.

Tkaczyk C, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G (2005). A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 280:9291-9296.

Tertian G, Yung YP, Guy-Grand D, Moore MA (1981). Long-term in vitro culture of murine mast cells. I. Description of a growth factor-dependent culture technique. J Immunol 127:788-794.

Thakurdas SM, Melicoff E, Sansores-Garcia L, Moreira DC, Petrova Y, Stevens RL, Adachi R (2007). The mast cell-restricted tryptase mMCP-6 has a critical immunoprotective role in bacterial infections. J Biol Chem 282:20809-20815.

Theiner G, Gessner A, Lutz MB (2006). The mast cell mediator PGD2 suppresses IL-12 release by dendritic cells leading to Th2 polarized immune responses in vivo. Immunobiology 211:463-472.

Thomas VA, Wheless CJ, Stack MS, Johnson DA (1998). Human mast cell tryptase fibrinogenolysis: kinetics, anticoagulation mechanism, and cell adhesion disruption. Biochemistry 37:2291-2298.

Thompson HL, Schulman ES, Metcalfe DD (1988). Identification of chondroitin sulfate E in human lung mast cells. J Immunol 140:2708-2713.

Thompson HL, Metcalfe DD, Kinet JP (1990). Early expression of high-affinity receptor for immunoglobulin E (Fc epsilon RI) during differentiation of mouse mast cells and human basophils. J Clin Invest 85:1227-1233.

Thompson-Snipes L, Dhar V, Bond MW, Mossmann TR, Moore KW, Rennick DM (1991). Interleukin 10: a growth factor-dependent culture technique. J Exp Med 173:507-510.

Tkaczyk C, Horejsi V, Iwaki S, Draber P, Samelson LE, Satterthwaite AB, Nahm DH, Metcalfe DD, Gilfillan AM (2004a). NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc epsilon RI aggregation. Blood 104:207-214.

Tkaczyk C, Okayama Y, Metcalfe D, Gilfillan A (2004b). Fcgamma receptors on mast cells: activatory and inhibitory regulation of mediator release. Int Arch Allergy Immunol 133:305-315.

Tkaczyk C, Jensen BM, Iwaki S, Gilfillan AM (2006). Adaptive and innate immune reactions regulating mast cell activation: from receptor-mediated signaling to responses. Immunol Allergy Clin North Am 26:427-450.

Toru H, Ra C, Nonoyama S, Suzuki K, Yata J, Nakahata T (1996). Induction of the high-affinity IgE receptor (Fc epsilon RI) on human mast cells by IL-4. Int Immunol 8:1367-1373.

Tori H, Eguchi M, Matsumoto R, Yanagida M, Yata J, Nakahata T (1998). Interleukin-4 promotes the development of tryptase and chymase double-positive human mast cells accompanied by cell maturation. Blood 91:187-195.

Trivedi NN, Caughey GH (2010). Mast cell peptidases: chameleons of innate immunity and host defense. Am J Respir Cell Mol Biol 42:257-267.

Tsujii K, Nakahata T, Takagi M, Kobayashi T, Ishiguro A, Kikuchi T, Naganuma K, Koike K, Miyajima A, Arai K (1990). Effects of interleukin-3 and interleukin-4 on the development of “connective tissue-type” mast cells: interleukin-3 supports their survival and interleukin-4 triggers and supports their proliferation synergistically with interleukin-3. Blood 75:421-427.

Tóth-Jakatics R, Jimi S, Takebayashi S, Kawamoto N (2000). Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells over-expressing vascular endothelial growth factor. Hum Pathol 31:955-960.

Uehara T, Bluéry M, Kang DW, Chen CC, Ho LH, Kartland GL, Liu FT, Vivier E, Cooper MD, Kubagawa H (2001). Inhibition of IgE-mediated mast cell activation by the paired Ig-like receptor PIR-B. J Clin Invest 108:1041-1050.

Urade Y, Ujihara M, Horiguchi Y, Igarashi M, Nagata A, Ikai K, Hayashi O (1990). Mast cells contain spleen-type prostaglandin D synthetase. J Biol Chem 265:371-375.

Valent P, Spanbøëchli E, Sperr WR, Sillaber C, Zsebo KM, Agis H, Strobl H, Geissler K, Bettelheim P, Lechner K (1992). Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/ligand in long-term culture. Blood 80:2237-2245.

Valent P, Horny E, Escribano L, Longley B, Li C, Schwartz L, Marone G, Nunez R, Akin C, Sotlar K, Sperr W, Wolff K, Brunning R, Parwaresch R, Austen K, Lennert K, Metcalfe D, Vardiman J, Bennett J (2001). Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leukemia Research 25:603-625.

Van Nassauw L, Adriaensen D, Timmermans JP (2007). The bidirectional communication between neurons and mast cells within the gastrointestinal tract. Auton Neurosci 133:91-103.

van Steensel L, Paridaens D, van Meurs M, van Hagen PM, van den Bosch WA, Kuijpers RW, Drexhage HA, Hooijkaas H, Dik WA (2012). Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves’ ophthalmopathy. J Clin Endocrinol Metab 97, E400-408.

Varadaradjalou S, Feger F, Thieblemont N, Hamouda NB, Pleau JM, Dy M, Arocé M (2003). Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol 33:899-906.

Venkatesha RT, Berla Thangam E, Zaidi AK, Ali H (2005). Distinct regulation of C3a-induced MCP-1/CCL2 and RANTES/CCL5 production in human mast cells by extracellular signal regulated kinase and PI3 kinase. Mol Immunol 42:581-587.
Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD (2001). Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 22:146-152.

Vermaelen KY, Carro-Muino I, Lambrecht BN, Pauwels RA (2001). Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J Exp Med 193:51-60.

von Kückritz-Blickwede M, Goldmann O, Thulin P, Heinemann K, Norby-Teplund A, Rohde M, Medina E (2008). Phagocytosis-independent antimicrobial activity of mast cells by means of extracellular trap formation. Blood 111: 3070-3080.

Waern I, Jonasson S, Hjoberg J, Bucht A, Abrink M, Pejler G, Wernersson S (2009). Mouse mast cell protease 4 is the major chymase in murine airways and has a protective role in allergic airway inflammation. J Immunol 183:6369-6376.

Waki N, Kitamura Y, Kanakura Y, Asai H, Nakano T (1990). Intraperitoneally injected cultured mast cells suppress recruitment and differentiation of bone marrow-derived mast cell precursors in the peritoneal cavity of W/Wv mice. Exp Hematol 18:243-247.

Wang Z, Lai Y, Bernard JJ, Cogen AL, Moss B, Didard O (2012). Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor 1IP2R and releasing antimicrobial peptides. J Immunol 188:345-357.

Weaver CT, Harrington LE, Mangan PR, Gavieli M, Murphy KM (2006). Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24:677-688.

Wei OL, Hilliard A, Kalman D, Sherman M (2005). Mast cells limit systemic bacterial dissemination but not colitis in response to Citrobacter rodentium. Infect Immun 73:1978-1985.

Welle M (1997). Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase. J Leukoc Biol 61:233-245.

Weller C, Collington S, Brown J, Miller H, Al-Kashi A, Clark P, Jose P, Hartnell A, Williams T (2005). Leukotriene B4, an activation product of mast cells, is a chemoattractant for their progenitors. J Exp Med 201:1961-1971.

Weller CL, Collington SJ, Williams T, Lamb JR (2011). Mast cells in health and disease. Clin Sci (Lond) 120:473-484.

Weller CL, Collington SJ, Hartnell A, Conroy DM, Kaise T, Barker JE, Wilson MS, Taylor GW, Jose PJ, Williams TJ (2007). Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor 3. Proc Natl Acad Sci U S A 104:11712-11717.

Whithead R (1980). Pathology of Crohn’s disease. In Inflammatory Bowel Disease., R.S. J Kirsner, ed (Philadelphia: Lea & Febiger), pp. 296–307.

WHO (2008). WHO classification of tumours of haematopoietic and lymphoid tissues (Lyon: International Agency for Research on Cancer).

Williams CM, Coleman JW (1995). Induced expression of mRNA for IL-5, IL-6, TNF-alpha, MIP-2 and IFN-gamma in immunologically activated rat peritoneal mast cells: inhibition by dexamethasone and cyclosporin A. Immunology 86:244-249.

Williams CM, Galli SJ (2000). The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J Allergy Clin Immunol 105:847-859.

Wintroub BU, Mihm MC, Goetzl EJ, Soter NA, Austen KF (1978). Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid. N Engl J Med 298:417-421.

Wodnar-Filipowicz A, Heussner CH, Moroni C (1989). Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation. Nature 339:150-152.

Wolters PJ, Luig-Webster M, Caughey GH (2000). Dipeptidyl pep-
tidase I cleaves matrix-associated proteins and is expressed mainly by mast cells in normal dog airways. Am J Respir Cell Mol Biol 22:183-190.

Woolley DE, Tetlow LC (2000). Mast cell activation and its rela-
tion to proinflammatory cytokine production in the rheu-
amatoid lesion. Arthritis Res 2:65-74.

Wright SH, Brown J, Knight PA, Thornton EM, Kilshaw PJ, Miller HR (2002). Transforming growth factor-beta mediates conversion of the integrin subunit alphaE and the chymase mouse mast cell protease-1 during the early differentiation of bone marrow-derived mucosal mast cell homologues. Clin Exp Allergy 32:315-324.

Wyczolkowska J, Rydzynski K, Prouvois-Manson A (1992). Concavalin A-induced activation of hamster mast-cells - Morphological changes and histamine secretion. International Archives of Allergy and Immunology 97:167-172.

Xiang Z, Block M, Löfman C, Nilsson G (2001). IgE-mediated mast cell degranulation and recovery monitored by time-lapse photography. J Allergy Clin Immunol 108:116-121.

Xing W, Austen KF, Gurish MF, Jones TG (2011). Protease phenotype of constitutive connective tissue and of induced mucosal mast cells in mice is regulated by the tissue. Proc Natl Acad Sci U S A 108:14210-14215.

Yamaguchi M, Lantz CS, Oetgen HC, Katona IM, Fleming T, Miyajima I, Kinet JP, Galli SJ (1997). IgE enhances mouse mast cell Fc epsilon RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. J Exp Med 185:663-672.

Yamamoto T, Katayama I, Nishioka K (1995). Mast cell numbers in multiple dermatofibromas. Dermatology 190:9-13.

Yanagida M, Fukamachi H, Ohgami K, Kuwaki T, Ishii H, Uzumaki H, Amano K, Tokiwa T, Matsu H, Saito H, Iikura Y, Ishizaka T, Nakahata T (1995). Effects of T-helper 2-type cytokines interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 86:3705-3714.

Yang F, Tran TA, Carlson JA, Hsi ED, Ross CW, Arber DA (2000). Paraffin section immunohistophenotypy of cutaneous and extracutaneous mast cell disease: comparison to other hematopoietic neoplasms. Am J Surg Pathol 24:703-709.

Yeatman CF, Jacobs-Helber SM, Mirmone SP, Gillespie SR, Bouton LA, Collins HA, Sawyer ST, Shelburne CP, Ryan JJ (2000). Combined stimulation with the T helper cell type 2 cytokines interleukin (IL)-4 and IL-10 induces mouse mast cell apoptosis. J Exp Med 192:1093-1103.

Yong LC (1997). The mast cell: origin, morphology, distribution, and function. Exp Toxicol Pathol 49:409-424.

Yoshii M, Jikuhara A, Mori S, Iwagaki H, Takahashi HK, Nishihori M, Tanaka N (2005). Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners. J Pharmacol Sci 98:450-458.
Yotsumoto K, Okoshi Y, Shibuya K, Yamazaki S, Tahara-Hanaoka S, Honda S, Osawa M, Karoiwa A, Matsuda Y, Tenen DG, Iwama A, Nakauchi H, Shibuya A (2003). Paired activating and inhibitory immunoglobulin-like receptors, MAIR-I and MAIR-II, regulate mast cell and macrophage activation. J Exp Med 198:223-233.

Yurt RW, Leid RW, Austen KF (1977). Native heparin from rat peritoneal mast cells. J Biol Chem 252:518-521.

Zhang C, Li X, Niu D, Zi R, Wang C, Han A, Wang X, Li K, Wang J (2011). Increased serum levels of β2-GPI-Lp(a) complexes and their association with premature atherosclerosis in patients with rheumatoid arthritis. Clin Chim Acta 412:1332-1336.

Zhang J, Billingsley ML, Kincaid RL, Siraganian RP (2000). Phosphorylation of Syk activation loop tyrosines is essential for Syk function. An in vivo study using a specific anti-Syk activation loop phosphotyrosine antibody. J Biol Chem 275:35442-35447.

Zhang S, Anderson DF, Bradding P, Coward WR, Baddeley SM, MacLeod JD, McGill JL, Church MK, Holgate ST, Roche WR (1998). Human mast cells express stem cell factor. J Pathol 186:59-66.

Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA (2004). Natural and induced CD4+CD25+ cells educate CD4+CD25−cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 172:5213-5221.

Zhou JS, Xing W, Friend DS, Austen KF, Katz HR (2007). Mast cell deficiency in Kit(W-sh) mice does not impair antibody-mediated arthritis. J Exp Med 204:2797-2802.

Zucker-Franklin D (1980). Ultrastructural evidence for the common origin of human mast cells and basophils. Blood 56:534-540.